


# Vitamin D

## Vitamin D

*Drug class*



Cholecalciferol (D<sub>3</sub>)

### Class identifiers

**Use** Rickets, osteoporosis, vitamin D deficiency

**ATC code** A11CC

**Biological target** vitamin D receptor

### Clinical data

**Drugs.com** MedFacts Natural Products

### External links

<b>MeSH</b>	D014807
In Wikidata	

**Vitamin D** is a group of fat-soluble **secosteroids** responsible for increasing intestinal absorption of **calcium**<sup>[1]</sup>, **magnesium**, and **phosphate**, and multiple other biological effects.<sup>[*citation needed*]</sup> In humans, the most important compounds in this group are vitamin D<sub>3</sub> (also known as **cholecalciferol**) and vitamin D<sub>2</sub> (**ergocalciferol**).<sup>[2]</sup> Cholecalciferol and ergocalciferol can be ingested from the diet and from supplements.<sup>[2][3][4]</sup> Only a few foods contain vitamin D. The major natural source of the vitamin is synthesis of cholecalciferol in the skin from **cholesterol** through a chemical reaction that is dependent on **sun exposure** (specifically **UVB radiation**). Dietary recommendations typically assume that all of a person's vitamin D is taken by mouth, as sun exposure in the population is variable and recommendations about the amount of sun exposure that is safe are uncertain in view of the **skin cancer risk**.<sup>[*citation needed*]</sup>

Vitamin D from the diet or skin synthesis is biologically inactive; enzymatic conversion (**hydroxylation**) in the liver and kidney is required for activation. As vitamin D can be synthesized in adequate amounts by most mammals exposed to sufficient sunlight, it is not an essential dietary factor, and so not technically a **vitamin**.<sup>[4]</sup> Instead it **could be considered as a hormone**, with activation of the vitamin D pro-hormone resulting in the active form, **calcitriol**, which then produces effects via a **nuclear receptor** in multiple different locations.<sup>[4]</sup> Cholecalciferol is converted in the liver to **calcifediol** (25-hydroxycholecalciferol); **ergocalciferol** is converted to 25-hydroxyergocalciferol. These two vitamin D metabolites (called 25-hydroxyvitamin D or 25(OH)D) are measured in serum to determine a person's vitamin D status.<sup>[5][6]</sup> Calcifediol is further hydroxylated by the kidneys to form **calcitriol** (also known as 1,25-dihydroxycholecalciferol), the biologically active form of vitamin D.<sup>[7]</sup> Calcitriol circulates as a hormone in the blood, having a major role regulating the concentration of **calcium** and **phosphate**, and promoting the healthy growth and remodeling of bone. Calcitriol also has other effects, including some on cell growth, neuromuscular and immune functions, and reduction of inflammation.<sup>[8]</sup>

Vitamin D has a significant role in **calcium homeostasis** and metabolism. Its discovery was due to effort to find the dietary substance lacking in children with **rickets** (the childhood form of **osteomalacia**).<sup>[9]</sup> Vitamin D supplements are given to treat or to prevent osteomalacia and rickets, but the evidence for other health effects of vitamin D supplementation in the general population is inconsistent.<sup>[10][11]</sup> The effect of vitamin D supplementation on mortality is not clear, with one meta-analysis finding a small decrease in mortality in elderly people,<sup>[12]</sup> and another concluding no clear justification exists for recommending supplementation for preventing many diseases, and that further research of similar design is unneeded in these areas.<sup>[13]</sup>

## Types


Name	Chemical composition	Structure
<b>Vitamin D<sub>1</sub></b>	Mixture of molecular compounds of <b>ergocalciferol</b> with <b>lumisterol</b> , 1:1	

Vitamin D <sub>2</sub>	<a href="#">ergocalciferol</a> (made from <a href="#">ergosterol</a> )	
Vitamin D <sub>3</sub>	<a href="#">cholecalciferol</a> (made from <a href="#">7-dehydrocholesterol</a> in the skin).	
Vitamin D <sub>4</sub>	<a href="#">22-dihydroergocalciferol</a>	
Vitamin D <sub>5</sub>	<a href="#">sitocalciferol</a> (made from <a href="#">7-dehydrositosterol</a> )	

Several forms ([vitamers](#)) of vitamin D exist. The two major forms are vitamin D<sub>2</sub> or ergocalciferol, and vitamin D<sub>3</sub> or cholecalciferol; vitamin D without a subscript refers to either D<sub>2</sub> or D<sub>3</sub> or both. These are known collectively as calciferol.<sup>[14]</sup> Vitamin D<sub>2</sub> was chemically characterized in 1931. In 1935, the [chemical structure](#) of vitamin D<sub>3</sub> was established and proven to result from the [ultraviolet irradiation](#) of 7-dehydrocholesterol.<sup>[15]</sup>

Chemically, the various forms of vitamin D are [secosteroids](#), i.e., [steroids](#) in which one of the bonds in the steroid rings is broken.<sup>[16]</sup> The structural difference between vitamin D<sub>2</sub> and vitamin D<sub>3</sub> is the side chain of D<sub>2</sub> contains a [double bond](#) between carbons 22 and 23, and a [methyl group](#) on carbon 24.

## Biology



[Calcium regulation](#) in the human body.<sup>[16]</sup> The role of active vitamin D (1,25-dihydroxyvitamin D, calcitriol) is shown in orange.

The active vitamin D metabolite calcitriol mediates its biological effects by binding to the [vitamin D receptor](#) (VDR), which is principally located in the [nuclei](#) of target cells.<sup>[16]</sup> The binding of calcitriol to the VDR allows the VDR to act as a [transcription factor](#) that modulates the [gene expression](#) of transport proteins (such as [TRPV6](#) and [calbindin](#)), which are involved in calcium absorption in the intestine.<sup>[17]</sup> The vitamin D receptor belongs to the [nuclear receptor](#) superfamily of [steroid/thyroid hormone receptors](#), and VDRs are expressed by cells in most [organs](#), including the [brain](#), [heart](#), skin, [gonads](#), [prostate](#), and [breast](#).

VDR activation in the intestine, bone, kidney, and parathyroid gland cells leads to the maintenance of calcium and phosphorus levels in the blood (with the assistance of parathyroid hormone and [calcitonin](#)) and to the maintenance of bone content.<sup>[1]</sup>

One of the most important roles of vitamin D is to maintain skeletal calcium balance by promoting [calcium absorption](#) in the intestines, promoting [bone resorption](#) by increasing [osteoclast](#) number, maintaining calcium and phosphate levels for [bone formation](#), and allowing proper functioning of parathyroid hormone to maintain serum calcium levels. [Vitamin D deficiency](#) can result in lower [bone mineral density](#) and an increased risk of reduced bone density ([osteoporosis](#)) or [bone fracture](#) because a lack of vitamin D alters mineral metabolism in the body.<sup>[18]</sup> Thus, vitamin D is also critical for [bone remodeling](#) through its role as a potent stimulator of [bone resorption](#).<sup>[18]</sup>

The VDR may be involved in [cell proliferation](#) and [differentiation](#). Vitamin D also affects the immune system, and VDRs are expressed in several [white blood cells](#), including [monocytes](#) and activated [T](#) and [B cells](#).<sup>[19]</sup> In vitro, vitamin D increases expression of the [tyrosine hydroxylase](#) gene in [adrenal medullary](#) cells, and affects the synthesis of [neurotrophic factors](#), [nitric oxide synthase](#), and [glutathione](#).<sup>[20]</sup>

## Deficiency

*Main article:* [Vitamin D deficiency](#)

A diet deficient in vitamin D in conjunction with inadequate sun exposure causes osteomalacia (or rickets when it occurs in children), which is a softening of the bones. In the developed world, this is a rare disease.<sup>[21][22]</sup> However, [vitamin D deficiency](#) has become a worldwide problem in the elderly and remains common in children and adults.<sup>[23][24]</sup> Low blood calcifediol (25-hydroxy-vitamin D) can result from avoiding the sun.<sup>[25]</sup> Deficiency results in impaired bone mineralization and bone damage which leads to bone-softening diseases,<sup>[26][27]</sup> including [rickets](#) and [osteomalacia](#).

Being deficient in vitamin D can cause intestinal absorption of dietary calcium to fall to 15%.<sup>[1]</sup> When not deficient, an individual usually absorbs between 60-80%.<sup>[1]</sup>

## Rickets

*Main article:* [Rickets](#)

**Rickets**, a childhood disease, is characterized by impeded growth and soft, weak, deformed **long bones** that bend and bow under their weight as children start to walk. This condition is characterized by bow legs,<sup>[27]</sup> which can be caused by calcium or phosphorus deficiency, as well as a lack of vitamin D; today, it is largely found in low-income countries in Africa, Asia, or the Middle East<sup>[28]</sup> and in those with genetic disorders such as pseudovitamin D deficiency rickets.<sup>[29]</sup>

Maternal **vitamin D deficiency** may cause overt bone disease from before birth and impairment of bone quality after birth.<sup>[30][31]</sup> Nutritional rickets exists in countries with intense year-round sunlight such as Nigeria and can occur without vitamin D deficiency.<sup>[32][33]</sup>

Although rickets and osteomalacia are now rare in Britain, outbreaks have happened in some immigrant communities in which osteomalacia sufferers included women with seemingly adequate daylight outdoor exposure wearing Western clothing.<sup>[34]</sup> Having darker skin and reduced exposure to sunshine did not produce rickets unless the diet deviated from a Western omnivore pattern characterized by high intakes of meat, fish, and eggs, and low intakes of high-extraction **cereals**.<sup>[35][36][37]</sup> The dietary risk factors for rickets include abstaining from animal foods.<sup>[34][38]</sup>

Vitamin D deficiency remains the main cause of rickets among young infants in most countries, because breast milk is low in vitamin D and social customs and climatic conditions can prevent adequate sun exposure. In sunny countries such as Nigeria, South Africa, and Bangladesh, where rickets occurs among older toddlers and children, it has been attributed to low dietary calcium intakes, which are characteristic of cereal-based diets with limited access to dairy products.<sup>[37]</sup>

Rickets was formerly a major public health problem among the US population; in **Denver**, where ultraviolet rays are about 20% stronger than at sea level on the same latitude,<sup>[39]</sup> almost two-thirds of 500 children had mild rickets in the late 1920s.<sup>[40]</sup> An increase in the proportion of animal protein<sup>[39][41]</sup> in the 20th century American diet coupled with increased consumption of milk<sup>[42][43]</sup> fortified with relatively small quantities of vitamin D coincided with a dramatic decline in the number of rickets cases.<sup>[41]</sup> Also, in the United States and Canada, vitamin D-fortified milk, infant vitamin supplements, and vitamin supplements have helped to eradicate the majority of cases of rickets for children with fat malabsorption conditions.<sup>[27]</sup>

## Osteomalacia

*Main article:* [Osteomalacia](#)

**Osteomalacia** is a disease in adults that results from vitamin D deficiency. Characteristics of this disease are softening of the bones, leading to bending of the spine, bowing of the legs, **proximal** muscle weakness, bone fragility, and increased risk for fractures.<sup>[44]</sup> Osteomalacia reduces calcium absorption and increases calcium loss from bone, which increases the risk for bone fractures. Osteomalacia is usually present when 25-hydroxyvitamin D levels are less than about 10 ng/mL.<sup>[2]</sup> Although the effects of osteomalacia are thought to contribute to chronic **musculoskeletal pain**,<sup>[45]</sup> there is no persuasive evidence of lower vitamin D levels in chronic pain sufferers<sup>[46]</sup> or that supplementation alleviates chronic nonspecific musculoskeletal pain.<sup>[47]</sup>

## Skin pigmentation

Dark-skinned people living in temperate climates have been shown to have low vitamin D levels but the significance of this is not certain.<sup>[48][49][50]</sup> Dark-skinned people may be less efficient at making vitamin D because melanin in the skin hinders vitamin D synthesis.<sup>[51]</sup>

## Use of supplements

The effects of vitamin D supplementation on health are uncertain.<sup>[1][52]</sup> A 2013 review did not find any effect from supplementation on the rates of disease, other than a tentative decrease in mortality in the elderly.<sup>[53]</sup> Vitamin D supplements do not alter the outcomes for **myocardial infarction**, **stroke** or **cerebrovascular disease**, cancer, **bone fractures** or knee **osteoarthritis**.<sup>[54][55]</sup> Low vitamin D levels may result from disease rather than cause disease.<sup>[53]</sup>

A United States **Institute of Medicine** report states: "Outcomes related to **cancer**, **cardiovascular disease** and **hypertension**, and **diabetes** and metabolic syndrome, falls and physical performance, immune functioning and **autoimmune disorders**, infections, neuropsychological functioning, and **preeclampsia** could not be linked reliably with calcium or vitamin D intake and were often conflicting."<sup>[56]</sup><sup>5</sup> Some researchers claim the IOM was too definitive in its recommendations and made a mathematical mistake when calculating the blood level of vitamin D associated with bone health.<sup>[57]</sup> Members of the IOM panel maintain that they used a "standard procedure for dietary recommendations" and that the report is solidly based on the data. Research on vitamin D supplements, including large-scale clinical trials, is continuing.<sup>[57]</sup>

## Mortality, all-cause

Vitamin D<sub>3</sub> supplementation has been tentatively found to lead to a reduced risk of death in the elderly,<sup>[12][53]</sup> but the effect has not been deemed pronounced or certain enough to make taking supplements recommendable.<sup>[13]</sup> Other forms (Vitamin D<sub>2</sub>, alfacalcidol, and calcitriol) do not appear to have any beneficial effects with regard to the risk of death.<sup>[12]</sup> High blood levels appear to be associated with a lower risk of death, but it is unclear if supplementation can result in this benefit.<sup>[58]</sup> Both an excess and a deficiency in vitamin D appear to cause abnormal functioning and premature aging.<sup>[59][60][61]</sup> The relationship between serum calcifediol level and all-cause mortality is parabolic.<sup>[66]</sup> Harm from vitamin D appears to occur at a lower vitamin D level in the black population than in the white population.<sup>[66]<sup>435</sup></sup>

## Bone health

In general, no good evidence supports the commonly held belief that vitamin D supplements can help prevent [osteoporosis](#).<sup>[13]</sup> Its general use for prevention of this disease in those without vitamin D deficiency is thus likely not needed.<sup>[62]</sup> For older people with osteoporosis, taking vitamin D with calcium may help prevent hip fractures, but it also slightly increases the risk of stomach and kidney problems.<sup>[63]</sup> Supplementation with higher doses of vitamin D, in those older than 65 years, may decrease fracture risk.<sup>[64]</sup> The effect is small or none for people living independently.<sup>[65][66]</sup> Low serum vitamin D levels have been associated with [falls](#), and low [bone mineral density](#).<sup>[67]</sup> Taking extra vitamin D, however, does not appear to change the risk.<sup>[68]</sup> Athletes who are vitamin D deficient are at an increased risk of [stress fractures](#) and/or major breaks, particularly those engaging in contact sports. The greatest benefit with supplementation is seen in athletes who are deficient (25(OH)D serum levels <30 ng/ml), or severely deficient (25(OH)D serum levels <25 ng/ml). Incremental decreases in risks are observed with rising serum 25(OH)D concentrations plateauing at 50 ng/ml with no additional benefits seen in levels beyond this point.<sup>[69]</sup>

Because it found mounting evidence for a benefit to bone health, though it had not found good evidence of other benefits, the US [Food and Drug Administration](#) has required manufacturers to declare the amount of vitamin D on [nutrition facts labels](#), as "nutrients of public health significance", since May 2016. By a proposed deadline extension, small manufacturers with less than \$10 million in annual food sales will have to comply by 1 Jan 2021, while larger ones have to comply by 1 Jan 2020.<sup>[70]</sup>

## Cancer

Vitamin D supplements have been widely marketed for their claimed anticancer properties.<sup>[71]</sup> Associations have been shown in observational studies between low vitamin D levels and the risk of development of certain cancers including colon cancer.<sup>[72]</sup> It is unclear, however, if taking additional vitamin D in the diet or as supplements affects the risk of [cancer](#). Reviews have described the evidence as being "inconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements"<sup>[66]</sup> and "not sufficiently robust to draw conclusions".<sup>[65]</sup> One 2014 review found that supplements had no significant effect on cancer risk.<sup>[13]</sup> Another 2014 review concluded that vitamin D<sub>3</sub> may decrease the risk of death from cancer (one fewer death in 150 people treated over 5 years), but concerns with the quality of the data were noted.<sup>[73]</sup> Insufficient evidence exists to recommend vitamin D supplements for people with cancer, although some evidence suggests that [low vitamin D](#) may be associated with a worse outcome for some cancers,<sup>[74]</sup> and that higher 25-hydroxy vitamin D levels at the time of diagnosis are associated with better outcomes.<sup>[75]</sup>

## Cardiovascular disease

Taking vitamin D supplements does not meaningfully reduce the risk of [stroke](#), [cerebrovascular disease](#), [cardial infarction](#), or [ischaemic heart disease](#).<sup>[13]</sup> Supplementation has no effect on [blood pressure](#).<sup>[76]</sup>

## Inflammatory Bowel Diseases (IBD)

Low levels of vitamin D are associated with two major forms of human [IBD](#): [Crohn's disease](#) and [ulcerative colitis](#).<sup>[77]</sup> In addition, vitamin D insufficiency is associated with alterations in gut microbiota.<sup>[78]</sup> However, further studies are required to determine its significance and the potential role of vitamin D axis in IBD.<sup>[77][79]</sup> Vitamin D<sub>3</sub> supplementation in IBD patients has controversial effects on disease activity.<sup>[80][81][82]</sup>

## Immune system

### Infectious diseases

In general, vitamin D functions to activate the [innate](#) and dampen the [adaptive immune systems](#).<sup>[83]</sup> Deficiency has been linked to increased risk or severity of [viral infections](#), including [HIV](#).<sup>[84][85]</sup> Low levels of vitamin D appear to be a

risk factor for [tuberculosis](#),<sup>[86]</sup> and historically it was used as a treatment.<sup>[87]</sup> Supplementation slightly decreases the risk of [respiratory tract infections](#) and the exacerbation of [asthma](#).<sup>[88][89][90]</sup> Evidence is lacking on whether it does so in children under five years of age.<sup>[91]</sup> No clinical trials have been done to assess its effect on preventing other infections, such as [malaria](#).

### Autoimmune diseases

Although tentative data link low levels of vitamin D to [asthma](#), evidence to support a beneficial effect on asthmatics from supplementation is inconclusive.<sup>[92]</sup> Accordingly, supplementation is not currently recommended for treatment or prevention of asthma.<sup>[93]</sup> Vitamin D and [multiple sclerosis](#) incidence have been linked, but it is not clear what the nature of any causal relationship might be.<sup>[94]</sup> There is no evidence that vitamin D supplementation is helpful for treating people with multiple sclerosis.<sup>[95]</sup>

## Other conditions

**Diabetes** -- A systematic review of 2014 concluded that the available studies show no evidence of vitamin D3 supplementation having an effect on glucose homeostasis or [diabetes](#) prevention.<sup>[96]</sup> A review article of 2016 reported that while there is increasing evidence that vitamin D deficiency may be a risk factor for diabetes, over-all evidence regarding vitamin D levels and diabetes mellitus is contradictory, requiring further studies.<sup>[97]</sup>

**Depression** -- Clinical trials of vitamin D supplementation for depressive symptoms have generally been of low quality and show no overall effect, although subgroup analysis showed supplementation for participants with clinically significant depressive symptoms or depressive disorder had a moderate effect.<sup>[98]</sup>

**Cognition and dementia** -- A systematic review of clinical studies found an association between low vitamin D levels, and [cognitive impairment](#) and a higher risk of developing [Alzheimer's disease](#). However, lower vitamin D concentrations are also associated with poor nutrition and spending less time outdoors. Therefore, alternative explanations for the increase in cognitive impairment exist and hence a direct causal relationship between vitamin D levels and cognition could not be established.<sup>[99]</sup>

**Pregnancy** -- Low levels of vitamin D in pregnancy are associated with [gestational diabetes](#), [pre-eclampsia](#), and small (for gestational age) infants.<sup>[100]</sup> Although taking vitamin D supplements during pregnancy raises blood levels of vitamin D in the mother at term,<sup>[101]</sup> the extent of benefits for the mother or baby is unclear.<sup>[100][101][102]</sup> Pregnant women who take an adequate amount of vitamin D during gestation may experience a lower risk of pre-eclampsia<sup>[101]</sup> and positive immune effects.<sup>[103]</sup> A 2018 review found that supplements may reduce the risk of undersized babies and of their poor rate of growth.<sup>[104]</sup> Pregnant women often do not take the recommended amount of vitamin D.<sup>[103]</sup>

**Weight loss** -- Though hypothesized that vitamin D supplementation may be an effective treatment for [obesity](#) apart from [calorie restriction](#), one systematic review found no association of supplementation with body weight or [fat mass](#).<sup>[105]</sup> A 2016 [meta-analysis](#) found that circulating vitamin D status was improved by weight loss, indicating that fat mass may be inversely associated with blood levels of vitamin D.<sup>[106]</sup>

## Allowable health claims

Governmental regulatory agencies stipulate for the food and dietary supplement industries certain health claims as allowable as statements on packaging.

### [European Food Safety Authority](#)

- normal function of the immune system<sup>[107]</sup>
- normal inflammatory response<sup>[107]</sup>
- normal muscle function<sup>[107]</sup>
- reduced risk of falling in people over age 60<sup>[108]</sup>

### US [Food and Drug Administration](#)

- "Adequate calcium and vitamin D, as part of a well balanced diet, along with physical activity, may reduce the risk of osteoporosis."<sup>[109]</sup>

### [Health Canada](#)

- Adequate calcium and regular exercise may help to achieve strong bones in children and adolescents and may reduce the risk of osteoporosis in older adults. An adequate intake of vitamin D is also necessary.<sup>[110]</sup>

Other possible agencies with claim guidance: Japan FOSHU<sup>[111]</sup> and Australia-New Zealand.<sup>[112]</sup>

## Dietary intake

### Recommended levels

United States		
Age group	RDA (IU/day)	(µg/day) <sup>[56]</sup>
Infants 0–6 months	400*	10
Infants 6–12 months	400*	10
1–70 years	600	15
71+ years	800	20
Pregnant/Lactating	600	15
* Adequate intake for infants, as an RDA has yet to be established <sup>[56]</sup>		
Age group	Tolerable upper intake level (IU/day)	(µg/day)
Infants 0–6 months	1,000	25
Infants 6–12 months	1,500	37.5
1–3 years	2,500	62.5
4–8 years	3,000	75
9+ years	4,000	100
Pregnant/lactating	4,000	100 <sup>[56]</sup>



**Canada**

Age group	RDA (IU)	Tolerable upper intake (IU) <sup>(113)</sup>
Infants 0–6 months	400*	1,000
Infants 7–12 months	400*	1,500
Children 1–3 years	600	2,500
Children 4–8 years	600	3,000
Children and Adults 9–70 years	600	4,000
Adults > 70 years	800	4,000
Pregnancy & Lactation	600	4,000

\* Adequate intake rather than recommended dietary allowance

**Australia and New Zealand**

Age group	Adequate Intake (µg)	Upper Level of Intake (µg) <sup>(114)</sup>
Infants 0–12 months	5	25
Children 1–18 years	5	80
Adults 19–50 years	5	80
Adults 51–70 years	10	80

Adults > 70 years	15	80
<b>European Food Safety Authority</b>		
Age group	Adequate Intake (µg) <sup>[115]</sup>	Tolerable upper limit (µg) <sup>[116]</sup>
Infants 0–12 months	10	25
Children 1–10 years	15	50
Children 11–17 years	15	100
Adults	15	100
Pregnancy & Lactation	15	100

Conversion: 1 µg = 40 IU.

Various institutions have proposed different recommendations for the amount of [daily intake](#) of vitamin D. These vary according to precise definition, age, pregnancy or lactation, and the extent assumptions are made regarding skin synthesis of vitamin D.<sup>[56][113][114][115]</sup>

### United States

The [dietary reference intake](#) for vitamin D issued in 2010 by the [Institute of Medicine](#) (IOM) for North America superseded previous recommendations which gave adequate intake values. The recommendations were formed assuming the individual has no skin synthesis of vitamin D because of inadequate sun exposure. The reference intake for vitamin D refers to total intake from food, beverages and supplements, and assumes that calcium requirements are being met.<sup>[56]:5</sup>

The [tolerable upper intake level](#) (UL) is defined as "the highest average daily intake of a nutrient that is likely to pose no risk of adverse health effects for nearly all persons in the general population."<sup>[56]:403</sup> Although tolerable upper intake levels are believed to be safe, information on the long-term effects is incomplete and these levels of intake are not recommended.<sup>[56]:403:433</sup>

For U.S. food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For vitamin D labeling purposes, 100% of the Daily Value was 400 IU (10 µg), but as of May 27, 2016 it was revised to 800 IU (20 µg) to bring it into agreement with the RDA.<sup>[117]</sup> The deadline to be in compliance was extended by the [FDA](#) to January 1, 2020 for large companies and January 1, 2021 for small companies.<sup>[118]</sup>

### Canada

[Health Canada](#) published recommended dietary allowances (RDA) and tolerable upper intake levels for vitamin D in 2012<sup>[113]</sup> based on the Institute of Medicine report.<sup>[56]</sup>

### Australia and New Zealand

Australia and New Zealand published nutrient reference values including guidelines for dietary vitamin D intake in 2005.<sup>[114]</sup> About a third of Australians have vitamin D deficiency.<sup>[119]</sup>

### European Union

The [European Food Safety Authority](#) (EFSA) in 2016<sup>[115]</sup> reviewed the current evidence, finding the relationship between serum 25(OH)D concentration and musculoskeletal health outcomes is widely variable. They considered that average requirements and population reference intakes values for vitamin D cannot be derived, and that a serum 25(OH)D concentration of 50 nmol/L was a suitable target value. For all people over the age of 1, including women who are pregnant or lactating, they set an adequate intake of 15 µg/day (600 IU).<sup>[115]</sup>

The EFSA reviewed safe levels of intake in 2012,<sup>[116]</sup> setting the tolerable upper limit for adults at 100 µg/day (4000 IU), a similar conclusion as the IOM.

The UK [National Health Service](#) recommends babies and young children aged six months to five years, pregnant or breastfeeding women, and sun-deprived elderly people should take daily vitamin supplements to ensure sufficient vitamin D intake.<sup>[120]</sup> In July 2016, [Public Health England](#) recommended that everyone consider taking a daily supplement containing 10 µg of vitamin D during autumn and winter because of inadequate sunlight for vitamin D synthesis.<sup>[121]</sup>

Non-government organisations in Europe have made their own recommendations. The German Society for Nutrition recommends 20 µg.<sup>[122]</sup> The European Menopause and Andropause Society recommends postmenopausal women consume 15 µg (600 IU) until age 70, and 20 µg (800 IU) from age 71. This dose should be increased to 100 µg (4,000 IU) in some patients with very low vitamin D status or in case of co-morbid conditions.<sup>[123]</sup>

## Sources

Although vitamin D is not present naturally in most foods,<sup>[214]</sup> it is commonly [added](#) as a [fortification](#) in manufactured foods. In some countries, staple foods are [artificially fortified](#) with vitamin D.<sup>[124]</sup>

### Natural sources

Main article: [Ergocalciferol § Biosynthesis](#)

In general, vitamin D<sub>2</sub> is found in [fungi](#) and vitamin D<sub>3</sub> is found in animals.<sup>[125][126]</sup> Vitamin D<sub>2</sub> is produced by ultraviolet irradiation of [ergosterol](#) found in many fungi. The vitamin D<sub>2</sub> content in mushrooms and [Cladonia arbuscula](#), a lichen, increase with exposure to ultraviolet light.<sup>[127][128]</sup> This process is emulated by industrial ultraviolet lamps, concentrating vitamin D<sub>2</sub> levels to higher levels.<sup>[126]</sup>

The [United States Department of Agriculture](#) reports D<sub>2</sub> and D<sub>3</sub> content combined in one value.

- Fungal sources
  - [C. arbuscula](#) ([lichen](#)), [thalli](#), dry: vitamin D<sub>3</sub> 0.67 to 2.04 µg/g (27 to 82 IU/g); vitamin D<sub>2</sub> 0.22-0.55 µg/g (8.8 to 22 IU/g).<sup>[127]</sup>
  - [Agaricus bisporus](#) (common mushroom), D<sub>2</sub> + D<sub>3</sub>, per 100 grams (3.5 oz):
    - raw portobello: 0.3 µg (10 IU); exposed to ultraviolet light: 11.2 µg (446 IU)
    - raw crimini: 0.1 µg (3 IU); exposed to ultraviolet light: 31.9 µg (1276 IU)
- Animal sources<sup>[129]</sup>
  - Fish liver oils, such as [cod liver oil](#), 450 IU per [teaspoon](#) (4.5 g); (100 IU/g)
  - Fatty fish species, such as:
    - [Salmon](#), pink, cooked, dry heat, 100 grams (3.5 oz): 522 IU (5.2 IU/g)
    - [Mackerel](#), Pacific and jack, mixed species, cooked, dry heat, 100 grams (3.5 oz): 457 IU (4.6 IU/g)
    - [Tuna](#), canned in oil, 100 grams (3.5 oz): 269 IU (2.7 IU/g)
    - [Sardines, canned in oil](#), drained, 100 grams (3.5 oz): 193 IU (1.9 IU/g)
  - Cooked [egg](#) yolk: 44 IU for a 61 g egg (0.7 IU/g)
  - Beef liver, cooked, braised, 100 grams (3.5 oz): 49 IU (0.5 IU/g)

### Food fortification

Manufactured foods fortified with Vitamin D include some fruit juices and fruit juice drinks, [meal replacement energy bars](#), [soy protein](#)-based beverages, certain cheese and cheese products, [flour](#) products, [infant formulas](#), many [breakfast cereals](#), and [milk](#).<sup>[130][131]</sup>

In 2016 in the United States, the Food and Drug Administration (FDA) amended food additive regulations for milk fortification,<sup>[132]</sup> stating that vitamin D<sub>3</sub> levels not exceed 42 IU vitamin D per 100 g (400 IU per US [quart](#)) of dairy milk, 84 IU of vitamin D<sub>2</sub> per 100 g (800 IU per quart) of [plant milks](#), and 89 IU per 100 g (800 IU per quart) in plant-based [yogurts](#).<sup>[133]</sup> Plant milks are defined as beverages made from soy, almond, rice, among other plant sources intended as alternatives to dairy milk.

While some studies have found that vitamin D<sub>3</sub> raises 25(OH)D blood levels faster and remains active in the body longer,<sup>[134][135]</sup> others contend that vitamin D<sub>2</sub> sources are equally bioavailable and effective as D<sub>3</sub> for raising and sustaining 25(OH)D.<sup>[126][136][137]</sup>

## Food preparation

Vitamin D content in typical foods is reduced variably by cooking. Boiled, fried and baked foods retained 69–89% of original vitamin D.<sup>[138]</sup>

## Recommended serum levels

---

See also: [Reference ranges for blood tests § Vitamins](#), and [Hypervitaminosis D § Ethnic differences](#)

Recommendations on recommended 25(OH)D serum levels vary across authorities, and vary based on factors like age.<sup>[8]</sup> US labs generally report 25(OH)D levels in ng/ml. Other countries often use nmol/L. One ng/ml is approximately equal to 2.5 nmol/L.

A 2014 review concluded that the most advantageous serum levels for 25(OH)D for all outcomes appeared to be close to 30 ng/ml (75 nmol/L).<sup>[139]</sup> The optimal vitamin D levels are still controversial and another review concluded that ranges from 30 to 40 ng/ml (75 to 100 nmol/L) were to be recommended for athletes.<sup>[140]</sup> Part of the controversy is because numerous studies have found differences in serum levels of 25(OH)D between ethnic groups; studies point to genetic as well as environmental reasons behind these variations.<sup>[141]</sup> Supplementation to achieve these standard levels could cause harmful vascular [calcification](#).<sup>[50]</sup>

A 2012 [meta-analysis](#) showed that the risk of [cardiovascular diseases](#) increases when blood levels of vitamin D are lowest in a range of 8 to 24 ng/ml (20 to 60 nmol/L), although results among the studies analyzed were inconsistent.<sup>[142]</sup>

In 2011 an [IOM](#) committee concluded a serum 25(OH)D level of 20 ng/ml (50 nmol/L) is needed for bone and overall health. The dietary reference intakes for vitamin D are chosen with a margin of safety and 'overshoot' the targeted serum value to ensure the specified levels of intake achieve the desired serum 25(OH)D levels in almost all persons. No contributions to serum 25(OH)D level are assumed from sun exposure and the recommendations are fully applicable to people with [dark skin](#) or negligible exposure to sunlight. The Institute found serum 25(OH)D concentrations above 30 ng/ml (75 nmol/L) are "not consistently associated with increased benefit". Serum 25(OH)D levels above 50 ng/ml (125 nmol/L) may be cause for concern. However, some people with serum 25(OH)D between 30 and 50 ng/ml (75 nmol/L-125 nmol/L) will also have inadequate vitamin D.<sup>[56]</sup>

## Excess

---

Further information: [hypervitaminosis D](#)

Vitamin D toxicity is rare.<sup>[24]</sup> It is caused by supplementing with high doses of vitamin D rather than sunlight. The threshold for vitamin D toxicity has not been established; however, according to some research, the tolerable upper intake level (UL) is 4,000 IU/day for ages 9–71<sup>[143]</sup> (100 µg/day), while other research concludes that, in healthy adults, sustained intake of more than 1250 µg/day (50,000 IU) can produce overt [toxicity](#) after several months and can increase serum 25-hydroxyvitamin D levels to 150 ng/ml and greater.<sup>[24][144]</sup> Those with certain medical conditions, such as primary [hyperparathyroidism](#),<sup>[145]</sup> are far more sensitive to vitamin D and develop [hypercalcemia](#) in response to any increase in vitamin D nutrition, while maternal hypercalcemia during pregnancy may increase fetal sensitivity to effects of vitamin D and lead to a syndrome of mental retardation and facial deformities.<sup>[145][146]</sup>

A review published in 2015 noted that adverse effects have been reported only at 25(OH)D serum concentrations above 200 nmol/L.<sup>[140]</sup>

Published cases of toxicity involving hypercalcemia in which the vitamin D dose and the 25-hydroxy-vitamin D levels are known all involve an intake of ≥40,000 IU (1,000 µg) per day.<sup>[145]</sup>

Pregnant or breastfeeding women should consult a doctor before taking a vitamin D supplement. The FDA advised manufacturers of liquid vitamin D supplements that droppers accompanying these products should be clearly and accurately marked for 400 [international units](#) (1 IU is the biological equivalent of 25 ng cholecalciferol/ergocalciferol). In addition, for products intended for infants, the FDA recommends the dropper hold no more than 400 IU.<sup>[147]</sup> For infants (birth to 12 months), the tolerable upper limit (maximum amount that can be tolerated without harm) is set at 25 µg/day (1,000 IU). One thousand micrograms per day in infants has produced toxicity within one month.<sup>[144]</sup> After being commissioned by the Canadian and American governments, the [Institute of Medicine](#) (IOM) as of

30 November 2010, has increased the tolerable upper limit (UL) to 2,500 IU per day for ages 1–3 years, 3,000 IU per day for ages 4–8 years and 4,000 IU per day for ages 9–71+ years (including pregnant or lactating women).<sup>[143]</sup>

Calcitriol itself is auto-regulated in a [negative feedback](#) cycle, and is also affected by [parathyroid hormone](#), [fibroblast growth factor 23](#), [cytokines](#), calcium, and phosphate.<sup>[148]</sup>

## Effect of excess

Vitamin D overdose causes hypercalcemia, which is a strong indication of vitamin D toxicity – this can be noted with an increase in urination and thirst. If hypercalcemia is not treated, it results in excess deposits of calcium in soft tissues and organs such as the kidneys, liver, and heart, resulting in pain and organ damage.<sup>[24][27][44]</sup>


The main symptoms of vitamin D overdose which are those of hypercalcemia including [anorexia](#), nausea, and vomiting. These may be followed by [polyuria](#), [polydipsia](#), weakness, insomnia, nervousness, [pruritus](#) and ultimately [renal failure](#). Furthermore, [proteinuria](#), [urinary casts](#), [azotemia](#), and [metastatic calcification](#) (especially in the kidneys) may develop.<sup>[144]</sup> Other symptoms of vitamin D toxicity include mental retardation in young children, abnormal bone growth and formation, diarrhea, irritability, weight loss, and severe depression.<sup>[24][44]</sup>

Vitamin D toxicity is treated by discontinuing vitamin D supplementation and restricting calcium intake. Kidney damage may be irreversible. Exposure to sunlight for extended periods of time does not normally cause vitamin D toxicity. The concentrations of vitamin D precursors produced in the skin reach an [equilibrium](#), and any further vitamin D produced is degraded.<sup>[145]</sup>


## Biosynthesis

Synthesis of vitamin D in nature is dependent on the presence of UV radiation and subsequent activation in liver and in kidney. Many animals synthesize vitamin D<sub>3</sub> from [7-dehydrocholesterol](#), and many fungi synthesize vitamin D<sub>2</sub> from [ergosterol](#).<sup>[125][126]</sup>

## Photochemistry



The photochemistry of vitamin D biosynthesis in animal and fungi




Thermal isomerization of [previtamin D<sub>3</sub>](#) to vitamin D<sub>3</sub>.

The transformation that converts 7-dehydrocholesterol to vitamin D<sub>3</sub> occurs in two steps.<sup>[149][150]</sup> First, 7-dehydrocholesterol is [photolyzed](#) by ultraviolet light in a 6-electron [conrotatory ring-opening electrocyclic reaction](#); the

product is [previtamin D<sub>3</sub>](#). Second, previtamin D<sub>3</sub> spontaneously [isomerizes](#) to vitamin D<sub>3</sub> ([cholecalciferol](#)) in an [antarafacial sigmatropic \[1,7\] hydride shift](#). At room temperature, the transformation of previtamin D<sub>3</sub> to vitamin D<sub>3</sub> in an organic solvent takes about 12 days to complete. The conversion of previtamin D<sub>3</sub> to vitamin D<sub>3</sub> in the skin is about 10 times faster than in an organic solvent.<sup>[151]</sup>

The conversion from ergosterol to vitamin D<sub>2</sub> follows a similar procedure, forming previtamin D<sub>2</sub> by photolysis, which isomerizes to vitamin D<sub>2</sub>.<sup>[152]</sup> The transformation of previtamin D<sub>2</sub> to vitamin D<sub>2</sub> in methanol has a rate comparable to that of previtamin D<sub>3</sub>. The process is faster in white button mushrooms.<sup>[153](fig. 3)</sup>

## Synthesis in the skin



In the epidermal strata of the skin, vitamin D production is greatest in the stratum basale (colored red in the illustration) and stratum spinosum (colored light brown).

Vitamin D<sub>3</sub> is produced photochemically from 7-dehydrocholesterol in the skin of most vertebrate animals, including humans.<sup>[154]</sup> The precursor of vitamin D<sub>3</sub>, 7-dehydrocholesterol is produced in relatively large quantities. 7-Dehydrocholesterol reacts with [UVB light](#) at [wavelengths](#) between 270 and 300 nm, with peak synthesis occurring between 295 and 297 nm.<sup>[155]</sup> These wavelengths are present in sunlight, as well as in the light emitted by the UV lamps in [tanning beds](#) (which produce ultraviolet primarily in the [UVA](#) spectrum, but typically produce 4% to 10% of the total UV emissions as UVB). Exposure to light through windows is insufficient because glass almost completely blocks UVB light.<sup>[156][157]</sup>

Adequate amounts of vitamin D can be produced with moderate sun exposure to the face, arms and legs, averaging 5–30 minutes twice per week, or approximately 25% of the time for minimal sunburn. The darker the skin, and the weaker the sunlight, the more minutes of exposure are needed. Vitamin D overdose is impossible from UV exposure; the skin reaches an equilibrium where the vitamin degrades as fast as it is created.<sup>[24][158][159]</sup>

[Sunscreen](#) absorbs or reflects ultraviolet light and prevents much of it from reaching the skin.<sup>[160]</sup> Sunscreen with a sun protection factor (SPF) of 8 based on the UVB spectrum decreases vitamin D synthetic capacity by 95%, and SPF 15 decreases it by 98%.<sup>[161]</sup>

The skin consists of two primary layers: the inner layer called the [dermis](#), composed largely of [connective tissue](#), and the outer, thinner [epidermis](#).<sup>[162]</sup> Thick epidermis in the soles and palms consists of five strata; from outer to inner, they are: the [stratum corneum](#), [stratum lucidum](#), [stratum granulosum](#), [stratum spinosum](#), and [stratum basale](#). Vitamin D is produced in the [keratinocytes](#)<sup>[163]</sup> of two innermost strata, the stratum basale and stratum spinosum.<sup>[160]</sup>

## Evolution

Vitamin D can be synthesized only by a photochemical process. Phytoplankton in the ocean (such as [coccolithophore](#) and [Emiliania huxleyi](#)) have been photosynthesizing vitamin D for more than 500 million years. Primitive vertebrates in the ocean could absorb calcium from the ocean into their skeletons and eat plankton rich in vitamin D.

Land vertebrates required another source of vitamin D other than plants for their calcified skeletons. They had to either ingest it or be exposed to sunlight to photosynthesize it in their skin.<sup>[125][151]</sup> Land vertebrates have been photosynthesizing vitamin D for more than 350 million years.<sup>[164]</sup>


In birds and fur-bearing mammals, fur or feathers block UV rays from reaching the skin. Instead, vitamin D is created from oily secretions of the skin deposited onto the feathers or fur, and is obtained orally during grooming.<sup>[165]</sup> However, some animals, such as the [naked mole-rat](#), are naturally cholecalciferol-deficient, as serum 25-OH vitamin D levels are undetectable.<sup>[166]</sup>

## Industrial synthesis

Vitamin D<sub>3</sub> (cholecalciferol) is produced industrially by exposing [7-dehydrocholesterol](#) to UVB light, followed by purification.<sup>[167]</sup> The 7-dehydrocholesterol is a natural substance in fish organs, especially the liver,<sup>[168]</sup> or in wool grease ([lanolin](#)) from sheep. Vitamin D<sub>2</sub> (ergocalciferol) is produced in a similar way using ergosterol from yeast or mushrooms as a starting material.<sup>[167][126]</sup>

## Mechanism of action

### Metabolic activation



Liver hydroxylation of [cholecalciferol](#) to [Calcifediol](#)

Kidney hydroxylation of calcifediol to [calcitriol](#)

Vitamin D is carried in the bloodstream to the liver, where it is converted into the [prohormone calcifediol](#). Circulating calcifediol may then be converted into [calcitriol](#), the biologically active form of vitamin D, in the kidneys.<sup>[169]</sup>

Whether it is made in the skin or ingested, Vitamin D is [hydroxylated](#) in the [liver](#) at position 25 (upper right of the molecule) to form 25-hydroxycholecalciferol (calcifediol or 25(OH)D).<sup>[170]</sup> This reaction is catalyzed by the [microsomal](#) enzyme [vitamin D 25-hydroxylase](#), the product of the *CYP2R1* human gene, and expressed by [hepatocytes](#).<sup>[171]</sup> Once made, the product is released into the [plasma](#), where it is bound to an  $\alpha$ -globulin carrier protein named the [vitamin D-binding protein](#).<sup>[172]</sup>

Calcifediol is transported to the proximal tubules of the kidneys, where it is hydroxylated at the 1- $\alpha$  position (lower right of the molecule) to form calcitriol (1,25-dihydroxycholecalciferol, 1,25(OH)<sub>2</sub>D). The conversion of calcifediol to calcitriol is catalyzed by the enzyme [25-hydroxyvitamin D<sub>3</sub> 1-alpha-hydroxylase](#), which is the product of the *CYP27B1* human gene. The activity of CYP27B1 is increased by [parathyroid hormone](#), and also by low calcium or phosphate.<sup>[4][169]</sup>

Following the final converting step in the kidney, calcitriol is released into the circulation. By binding to vitamin D-binding protein, calcitriol is transported throughout the body, including to the classical target organs of intestine, kidney and bone.<sup>[15]</sup> Calcitriol is the most potent natural [ligand](#) of the [vitamin D receptor](#), which mediates most of the physiological actions of vitamin D.<sup>[4][169]</sup>

In addition to the kidneys, calcitriol is also synthesized by certain other cells including [monocyte-macrophages](#) in the [immune system](#). When synthesized by monocyte-macrophages, calcitriol acts locally as a [cytokine](#), modulating body defenses against microbial invaders by stimulating the [innate immune system](#).<sup>[169]</sup>

## Inactivation

The activity of calcifediol and calcitriol can be reduced by hydroxylation at position 24 by [vitamin D3 24-hydroxylase](#), forming secalciferol and calcitretol respectively.<sup>[170]</sup>

## Difference between substrates

Vitamin D<sub>2</sub> (ergocalciferol) and Vitamin D<sub>3</sub> (cholecalciferol) share a similar mechanism of action as outlined above.<sup>[170]</sup> Metabolites produced by vitamin D<sub>2</sub> is sometimes named with a *er-* or *ergo* prefix to differentiate them from the D<sub>3</sub>-based counterparts.<sup>[173]</sup> Nevertheless, these differences are present in the metabolism of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub>.<sup>[170]</sup>

- Metabolites produced from Vitamin D<sub>2</sub> tend to bind less well to the vitamin D-binding protein.
- Vitamin D<sub>3</sub> can alternatively be hydroxylated to calcifediol by [sterol 27-hydroxylase](#) (CYP27A1), but Vitamin D<sub>2</sub> can not.
- Ergocalciferol can be directly hydroxylated at position 24. The inactivation also tends to have a more profound effect: while calcitriol's activity decreases to 60% of original after 24-hydroxylation,<sup>[174]</sup> ercalcitriol suffers a 10-fold decrease in activity on conversion to ercalcitretol.<sup>[175]</sup>

## History

American researchers [Elmer McCollum](#) and [Marguerite Davis](#) in 1914<sup>[91]</sup> discovered a substance in [cod liver oil](#) which later was called "vitamin A". British doctor [Edward Mellanby](#) noticed dogs that were fed cod liver oil did not develop rickets and concluded vitamin A, or a closely associated factor, could prevent the disease. In 1922, Elmer McCollum tested modified cod liver oil in which the vitamin A had been destroyed.<sup>[91]</sup> The modified oil cured the sick dogs, so McCollum concluded the factor in cod liver oil which cured rickets was distinct from vitamin A. He called it vitamin D because it was the fourth vitamin to be named.<sup>[176][177][178]</sup> It was not initially realized that, unlike other vitamins, vitamin D can be synthesised by humans through exposure to UV light.

In 1925,<sup>[91]</sup> it was established that when 7-dehydrocholesterol is irradiated with light, a form of a [fat-soluble](#) vitamin is produced (now known as D<sub>3</sub>). [Alfred Fabian Hess](#) stated: "Light equals vitamin D."<sup>[179]</sup> [Adolf Windaus](#), at the [University of Göttingen](#) in Germany, received the [Nobel Prize in Chemistry](#) in 1928 for his work on the constitution of sterols and their connection with vitamins.<sup>[180]</sup> In 1929, a group at [NIMR](#) in Hampstead, London, were working on the structure of vitamin D, which was still unknown, as well as the structure of steroids. A meeting took place with [J.B.S. Haldane](#), [J.D. Bernal](#), and [Dorothy Crowfoot](#) to discuss possible structures, which contributed to bringing a team together. X-ray crystallography demonstrated the sterol molecules were flat, not as proposed by the German team led by Windaus. In 1932, Otto Rosenheim and Harold King published a paper putting forward structures for sterols and bile acids which found immediate acceptance.<sup>[181]</sup> The informal academic collaboration between the team members Robert Benedict Bourdillon, Otto Rosenheim, Harold King, and [Kenneth Callow](#) was very productive and led to the isolation and characterization of vitamin D.<sup>[182]</sup> At this time, the policy of the [Medical Research Council](#) was not to patent discoveries, believing the results of medical research should be open to everybody. In the 1930s, Windaus clarified further the chemical structure of vitamin D.<sup>[183]</sup>

In 1923, American biochemist [Harry Steenbock](#) at the [University of Wisconsin](#) demonstrated that irradiation by ultraviolet light increased the vitamin D content of foods and other organic materials.<sup>[184]</sup> After irradiating rodent food, Steenbock discovered the rodents were cured of rickets. A vitamin D deficiency is a known cause of rickets. Using \$300 of his own money, Steenbock patented his invention. His irradiation technique was used for foodstuffs, most memorably for milk. By the expiration of his patent in 1945, rickets had been all but eliminated in the US.<sup>[185]</sup>

In 1969, after studying nuclear fragments of intestinal cells, a specific binding protein for Vitamin D called the [Vitamin D Receptor](#) was identified by Mark Haussler and [Tony Norman](#).<sup>[186]</sup> In 1971–72, the further metabolism of vitamin D to active forms was discovered. In the liver, vitamin D was found to be converted to calcifediol. Calcifediol is then converted by the kidneys to calcitriol, the biologically active form of vitamin D.<sup>[71]</sup> Calcitriol circulates as a hormone in the blood, regulating the concentration of calcium and phosphate in the bloodstream and promoting the healthy growth and remodeling of bone. The vitamin D metabolites, calcifediol and calcitriol, were identified by competing teams led by [Michael F. Holick](#) in the laboratory of [Hector DeLuca](#) and by [Tony Norman](#) and colleagues.<sup>[187][188][189]</sup>





12. <sup>^</sup> [to:##\\$#f](#) Bolland MJ, Grey A, Gamble GD, Reid IR (April 2014). "The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis". *The Lancet Diabetes & Endocrinology (Meta-analysis)*. **2** (4): 307–20. [doi:10.1016/S2213-8587\(13\)70212-2](#). [PMID 24703049](#).
13. <sup>^</sup> [Dorland's Illustrated Medical Dictionary](#), under Vitamin (Table of Vitamins)
14. <sup>^</sup> [to:##\\$# "About Vitamin D"](#). University of California, Riverside. November 2011. Retrieved January 24, 2015.
15. <sup>^</sup> [Boron WF, Boulpaep EL](#) (29 March 2016). *Medical Physiology E-Book*. Elsevier Health Sciences. [ISBN 978-1-4557-3328-6](#).
16. <sup>^</sup> [Bouillon R, Van Cromphaut S, Carmeliet G](#) (February 2003). "Intestinal calcium absorption: Molecular vitamin D mediated mechanisms". *Journal of Cellular Biochemistry*. **88** (2): 332–9. [doi:10.1002/jcb.10360](#). [PMID 12520535](#).
17. <sup>^</sup> [to:## Bell TD, Demay MB, Burnett-Bowie SA](#) (September 2010). "*The biology and pathology of vitamin D control in bone*". *Journal of Cellular Biochemistry*. **111** (1): 7–13. [doi:10.1002/jcb.22661](#). [PMC 4020510](#)  [PMID 20506379](#).
18. <sup>^</sup> [Watkins RR, Lemonovich TL, Salata RA](#) (May 2015). "*An update on the association of vitamin D deficiency with common infectious diseases*". *Canadian Journal of Physiology and Pharmacology*. **93** (5): 363–8. [doi:10.1139/cjpp-2014-0352](#). [PMID 25741906](#).
19. <sup>^</sup> [Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK](#) (February 1996). "Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells". *Brain Research. Molecular Brain Research*. **36** (1): 193–6. [doi:10.1016/0169-328X\(95\)00314-I](#). [PMID 9011759](#).
20. <sup>^</sup> ["Rickets"](#). [National Health Service](#). March 8, 2012. Retrieved July 9, 2012.
21. <sup>^</sup> [MedlinePlus Encyclopedia Rickets](#)
22. <sup>^</sup> [Eriksen EF, Glerup H](#) (2002). "Vitamin D deficiency and aging: implications for general health and osteoporosis". *Biogerontology*. **3** (1–2): 73–7. [doi:10.1023/A:1015263514765](#). [PMID 12014847](#).
23. <sup>^</sup> [to:##\\$#f Holick MF](#) (July 2007). "Vitamin D deficiency". *The New England Journal of Medicine*. **357** (3): 266–81. [doi:10.1056/NEJMr070553](#). [PMID 17634462](#).
24. <sup>^</sup> [Schoenmakers I, Goldberg GR, Prentice A](#) (June 2008). "*Abundant sunshine and vitamin D deficiency*". *The British Journal of Nutrition*. **99** (6): 1171–3. [doi:10.1017/S0007114508898662](#). [PMC 2758994](#)  [PMID 18234141](#).
25. <sup>^</sup> [Grant WB, Holick MF](#) (June 2005). "Benefits and requirements of vitamin D for optimal health: a review". *Alternative Medicine Review*. **10** (2): 94–111. [PMID 15989379](#).
26. <sup>^</sup> [to:##\\$# Brown JE, Isaacs J, Krinke B, Lechtenberg E, Murtaugh M](#) (28 June 2013). *Nutrition Through the Life Cycle*. Cengage Learning. [ISBN 978-1-285-82025-5](#).
27. <sup>^</sup> [Lerch C, Meissner T](#) (October 2007). Lerch C, ed. "Interventions for the prevention of nutritional rickets in term born children". *The Cochrane Database of Systematic Reviews* (4): CD006164. [doi:10.1002/14651858.CD006164.pub2](#). [PMID 17943890](#).
28. <sup>^</sup> [Zargar AH, Mithal A, Wani AI, Laway BA, Masoodi SR, Bashir MI, Ganie MA](#) (June 2000). "*Pseudovitamin D deficiency rickets--a report from the Indian subcontinent*". *Postgraduate Medical Journal*. **76** (896): 369–72. [doi:10.1136/pmj.76.896.369](#). [PMC 1741602](#)  [PMID 10824056](#).
29. <sup>^</sup> [Elidrissy AT](#) (September 2016). "The Return of Congenital Rickets, Are We Missing Occult Cases?". *Calcified Tissue International (Review)*. **99** (3): 227–36. [doi:10.1007/s00223-016-0146-2](#). [PMID 27245342](#).
30. <sup>^</sup> [Paterson CR, Ayoub D](#) (October 2015). "Congenital rickets due to vitamin D deficiency in the mothers". *Clinical Nutrition(Review)*. **34** (5): 793–8. [doi:10.1016/j.clnu.2014.12.006](#). [PMID 25552383](#).
31. <sup>^</sup> [Oramasionwu GE, Thacher TD, Pam SD, Pettifor JM, Abrams SA](#) (August 2008). "Adaptation of calcium absorption during treatment of nutritional rickets in Nigerian children". *The British Journal of Nutrition*. **100** (2): 387–92. [doi:10.1017/S0007114507901233](#). [PMID 18197991](#).
32. <sup>^</sup> [Fischer PR, Rahman A, Cimma JP, Kyaw-Myint TO, Kabir AR, Talukder K, Hassan N, Manaster BJ, Staab DB, Duxbury JM, Welch RM, Meisner CA, Haque S, Combs GF](#) (October 1999). "Nutritional rickets without vitamin D deficiency in Bangladesh". *Journal of Tropical Pediatrics*. **45** (5): 291–3. [doi:10.1093/tropej/45.5.291](#). [PMID 10584471](#).
33. <sup>^</sup> [to:##\\$# Dunnigan MG, Henderson JB](#) (November 1997). "An epidemiological model of privational rickets and osteomalacia". *The Proceedings of the Nutrition Society*. **56** (3): 939–56. [doi:10.1079/PNS19970100](#). [PMID 9483661](#).
34. <sup>^</sup> [Robertson I, Ford JA, McIntosh WB, Dunnigan MG](#) (January 1981). "The role of cereals in the aetiology of nutritional rickets: the lesson of the Irish National Nutrition Survey 1943-8". *The British Journal of Nutrition*. **45** (1): 17–22. [doi:10.1079/BJN19810073](#). [PMID 6970590](#).
35. <sup>^</sup> [Clements MR](#) (1989). "The problem of rickets in UK Asians". *Journal of Human Nutrition and Dietetics*. **2** (2): 105–116. [doi:10.1111/j.1365-277X.1989.tb00015.x](#).
36. <sup>^</sup> [to:##\\$# Pettifor JM](#) (December 2004). "Nutritional rickets: deficiency of vitamin D, calcium, or both?". *The American Journal of Clinical Nutrition*. **80** (6 Suppl): 1725S–9S. [PMID 15585795](#).
37. <sup>^</sup> [to:##\\$# Dunnigan MG, Henderson JB, Hole DJ, Barbara Mawer E, Berry JL](#) (December 2005). "Meat consumption reduces the risk of nutritional rickets and osteomalacia". *The British Journal of Nutrition*. **94** (6): 983–91. [doi:10.1079/BJN20051558](#). [PMID 16351777](#).
38. <sup>^</sup> ["US National Institutes Of Health, National Cancer Institute"](#). [Science.education.nih.gov](#). Archived from [the original](#) on June 8, 2010. Retrieved August 24, 2010.
39. <sup>^</sup> [Weick MT](#) (November 1967). "A history of rickets in the United States". *The American Journal of Clinical Nutrition*. **20** (11): 1234–41. [PMID 4862158](#).
40. <sup>^</sup> [Garrison RH, Somer E](#) (1997). *The Nutrition Desk Reference*. McGraw-Hill. [ISBN 978-0-87983-826-3](#).
41. <sup>^</sup> [Dupuis, E. Melanie](#) (1 February 2002). *Nature's Perfect Food: How Milk Became America's Drink*. NYU Press. [ISBN 978-0-8147-1938-1](#).

42. [^ Teegarden D, Lyle RM, Proulx WR, Johnston CC, Weaver CM \(May 1999\). "Previous milk consumption is associated with greater bone density in young women". \*The American Journal of Clinical Nutrition\*. \*\*69\*\* \(5\): 1014–7. PMID 10232644.](#)
43. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> Insel P, Ross D, Bernstein M, McMahon K \(18 March 2015\). \*Discovering Nutrition\*. Jones & Bartlett Publishers. ISBN 978-1-284-06465-0.](#)
44. [^ Holick MF \(February 2003\). "Vitamin D: A millenium perspective". \*Journal of Cellular Biochemistry\*. \*\*88\*\* \(2\): 296–307. doi:10.1002/jcb.10338. PMID 12520530.](#)
45. [^ Straube S, Andrew Moore R, Derry S, McQuay HJ \(January 2009\). "Vitamin D and chronic pain". \*Pain\*. \*\*141\*\* \(1–2\): 10–3. doi:10.1016/j.pain.2008.11.010. PMID 19084336.](#)
46. [^ Gaikwad M, Vanlint S, Mittinity M, Moseley GL, Stocks N \(February 2016\). "Does vitamin D supplementation alleviate chronic nonspecific musculoskeletal pain? A systematic review and meta-analysis". \*Clinical Rheumatology\*. doi:10.1007/s10067-016-3205-1. PMID 26861032.](#)
47. [^ Lowe NM, Bhojani I \(June 2017\). "Special considerations for vitamin D in the south Asian population in the UK". \*Therapeutic Advances in Musculoskeletal Disease\*. \*\*9\*\* \(6\): 137–144. doi:10.1177/1759720X17704430. PMC 5466148. PMID 28620422.](#)
48. [^ O'Connor MY, Thoreson CK, Ramsey NL, Ricks M, Sumner AE \(2013\). "The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature". \*Progress in Cardiovascular Diseases \(Review\)\*. \*\*56\*\* \(3\): 261–9. doi:10.1016/j.pcad.2013.10.015. PMC 3894250. PMID 24267433.](#)
49. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> Freedman BI, Register TC \(June 2012\). "Effect of race and genetics on vitamin D metabolism, bone and vascular health". \*Nature Reviews. Nephrology \(Review\)\*. \*\*8\*\* \(8\): 459–66. doi:10.1038/nrneph.2012.112. PMID 22688752.](#)
50. [^ Khalid AT, Moore CG, Hall C, Olabopo F, Rozario NL, Holick MF, Greenspan SL, Rajakumar K \(September 2017\). "Utility of sun-reactive skin typing and melanin index for discerning vitamin D deficiency". \*Pediatric Research\*. \*\*82\*\* \(3\): 444–451. doi:10.1038/pr.2017.114. PMC 5570640. PMID 28467404.](#)
51. [^ Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP \(April 2014\). "Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials". \*BMJ\*. \*\*348\*\*: g2035. doi:10.1136/bmj.g2035. PMC 3972415. PMID 24690624.](#)
52. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> Autier P, Boniol M, Pizot C, Mullie P \(January 2014\). "Vitamin D status and ill health: a systematic review". \*The Lancet Diabetes & Endocrinology\*. \*\*2\*\* \(1\): 76–89. doi:10.1016/S2213-8587\(13\)70165-7. PMID 24622671.](#)
53. [^ Bolland MJ, Grey A, Gamble GD, Reid IR \(April 2014\). "The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis". \*The Lancet Diabetes & Endocrinology\*. \*\*2\*\* \(4\): 307–20. doi:10.1016/S2213-8587\(13\)70212-2. PMID 24703049.](#)
54. [^ Hussain S, Singh A, Akhtar M, Najmi AK \(September 2017\). "Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials". \*Rheumatology International\*. \*\*37\*\* \(9\): 1489–1498. doi:10.1007/s00296-017-3719-0. PMID 28421358.](#)
55. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> <sup>e</sup> <sup>f</sup> <sup>g</sup> <sup>h</sup> <sup>i</sup> <sup>j</sup> <sup>k</sup> <sup>l</sup> <sup>m</sup> Ross AC, Taylor CL, Yaktine AL, Del Valle HB \(2011\). \*Dietary Reference Intakes for Calcium and Vitamin D\*. Washington, D.C: National Academies Press. ISBN 0-309-16394-3.](#)
56. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> Maxmen A \(July 2011\). "Nutrition advice: the vitamin D-lemma". \*Nature\*. \*\*475\*\* \(7354\): 23–5. doi:10.1038/475023a. PMID 21734684.](#)
57. [^ Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot LD, Streppel M, Gardiner J, Ordóñez-Mena JM, Perna L, Wilsgaard T, Rathmann W, Feskens E, Kampman E, Siganos G, Njølstad I, Mathiesen EB, Kubínová R, Paják A, Topor-Madry R, Tamosiunas A, Hughes M, Kee F, Bobak M, Trichopoulou A, Boffetta P, Brenner H \(June 2014\). "Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States". \*BMJ\*. \*\*348\*\* \(jun17 16\): g3656. doi:10.1136/bmj.g3656. PMC 4061380. PMID 24938302.](#)
58. [^ Tuohimaa P \(March 2009\). "Vitamin D and aging". \*The Journal of Steroid Biochemistry and Molecular Biology\*. \*\*114\*\* \(1–2\): 78–84. doi:10.1016/j.jsbmb.2008.12.020. PMID 19444937.](#)
59. [^ Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A \(December 2009\). "Vitamin D, nervous system and aging". \*Psychoneuroendocrinology\*. \*\*34\*\* Suppl 1: S278–86. doi:10.1016/j.psyneuen.2009.07.003. PMID 19660871.](#)
60. [^ Manyá H, Akasaka-Manyá K, Endo T \(July 2010\). "Klotho protein deficiency and aging". \*Geriatrics & Gerontology International\*. \*\*10\*\* Suppl 1 \(Suppl 1\): S80–7. doi:10.1111/j.1447-0594.2010.00596.x. PMID 20590845.](#)
61. [^ Reid IR, Bolland MJ, Grey A \(January 2014\). "Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis". \*Lancet\*. \*\*383\*\* \(9912\): 146–55. doi:10.1016/s0140-6736\(13\)61647-5. PMID 24119980.](#)
62. [^ Avenell A, Mak JC, O'Connell D \(April 2014\). "Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men". \*The Cochrane Database of Systematic Reviews\*. \*\*4\*\* \(4\): CD000227. doi:10.1002/14651858.CD000227.pub4. PMID 24729336.](#)
63. [^ Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B \(July 2012\). "A pooled analysis of vitamin D dose requirements for fracture prevention". \*The New England Journal of Medicine\*. \*\*367\*\* \(1\): 40–9. doi:10.1056/NEJMoa1109617. PMID 22762317.](#)
64. [^ <sup>a</sup> <sup>b</sup> <sup>c</sup> <sup>d</sup> Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA \(December 2011\). "Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force". \*Annals of Internal Medicine\*. \*\*155\*\* \(12\): 827–38. doi:10.7326/0003-4819-155-12-201112200-00005. PMID 22184690.](#)
65. [^ Zhao JG, Zeng XT, Wang J, Liu L \(December 2017\). "Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis". \*JAMA\*. \*\*318\*\* \(24\): 2466–2482. doi:10.1001/jama.2017.19344. PMID 29279934.](#)

66. [Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garrity C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V \(August 2007\). "Effectiveness and safety of vitamin D in relation to bone health". Evidence Report/Technology Assessment \(158\): 1–235. \[PMC 4781354\]\(#\) !\[\]\(effbd7993c63c039a58fd3395789cf3f\_img.jpg\) \[PMID 18088161\]\(#\).](#)
67. [Bolland MJ, Grey A, Gamble GD, Reid IR \(July 2014\). "Vitamin D supplementation and falls: a trial sequential meta-analysis". The Lancet Diabetes & Endocrinology. 2 \(7\): 573–80. \[doi:10.1016/S2213-8587\\(14\\)70068-3\]\(#\). \[PMID 24768505\]\(#\).](#)
68. [Shuler FD, Wingate MK, Moore GH, Giangarra C \(November 2012\). "Sports health benefits of vitamin d". Sports Health. 4\(6\): 496–501. \[doi:10.1177/1941738112461621\]\(#\). \[PMC 3497950\]\(#\) !\[\]\(144980d038f2541d7b588a8a9132bd70\_img.jpg\) \[PMID 24179588\]\(#\).](#)
69. [Proposed Changes to the Nutrition Facts Label. FDA.gov \(2016-05-20\)](#)
70. [Byers T \(July 2010\). "Anticancer vitamins du Jour--The ABCED's so far". American Journal of Epidemiology \(Review\). 172 \(1\): 1–3. \[doi:10.1093/aje/kwq112\]\(#\). \[PMC 2892535\]\(#\) !\[\]\(c4ce2d477989700c971cf3d240ad9283\_img.jpg\) \[PMID 20562190\]\(#\).](#)
71. [Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ \(May 2014\). "The role of vitamin D in reducing cancer risk and progression". Nature Reviews. Cancer. 14 \(5\): 342–57. \[doi:10.1038/nrc3691\]\(#\). \[PMID 24705652\]\(#\).](#)
72. [Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C \(January 2014\). "Vitamin D supplementation for prevention of mortality in adults". The Cochrane Database of Systematic Reviews. 1 \(1\): CD007470. \[doi:10.1002/14651858.cd007470.pub3\]\(#\). \[PMID 24414552\]\(#\).](#)
73. [Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, Berruti A \(2011\). "Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review". The Oncologist. 16 \(9\): 1215–27. \[doi:10.1634/theoncologist.2011-0098\]\(#\). \[PMC 3228169\]\(#\) !\[\]\(5013555a72072875cb154b597e002a46\_img.jpg\) \[PMID 21835895\]\(#\).](#)
74. [Li M, Chen P, Li J, Chu R, Xie D, Wang H \(July 2014\). "Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 99 \(7\): 2327–36. \[doi:10.1210/jc.2013-4320\]\(#\). \[PMID 24780061\]\(#\).](#)
75. [Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. \(May 2015\). "Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data". JAMA Internal Medicine. 175 \(5\): 745–54. \[doi:10.1001/jamainternmed.2015.0237\]\(#\). \[PMID 25775274\]\(#\).](#)
76. [to<sup>a</sup> Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F \(November 2015\). "Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis". Inflammatory Bowel Diseases. 21 \(11\): 2708–17. \[doi:10.1097/MIB.0000000000000546\]\(#\). \[PMC 4615394\]\(#\) !\[\]\(bf2038c114ec21ea58ad011774351c98\_img.jpg\) \[PMID 26348447\]\(#\).](#)
77. [Kanhere M, He J, Chassaing B, Ziegler TR, Alvarez JA, Ivie EA, Hao L, Hanfelt J, Gewirtz AT, Tangpricha V \(February 2018\). "Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial". The Journal of Clinical Endocrinology and Metabolism. 103 \(2\): 564–574. \[doi:10.1210/jc.2017-01983\]\(#\). \[PMC 5800825\]\(#\) !\[\]\(1ad0c3425edfa4762c2f20e33e3e5bbf\_img.jpg\) \[PMID 29161417\]\(#\).](#)
78. [Del Pinto R, Ferri C, Cominelli F \(November 2017\). "Vitamin D Axis in Inflammatory Bowel Diseases: Role, Current Uses and Future Perspectives". International Journal of Molecular Sciences. 18 \(11\): 2360. \[doi:10.3390/ijms18112360\]\(#\). \[PMC 5713329\]\(#\) !\[\]\(74d2fc5645add84f8511beb934060048\_img.jpg\) \[PMID 29112157\]\(#\).](#)
79. [Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, Quinn N, Lawton RC, Bronzwaer ME, Koenen M, Gordon CM \(September 2014\). "Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens". The Journal of Clinical Endocrinology and Metabolism. 99 \(9\): 3408–17. \[doi:10.1210/jc.2013-4218\]\(#\). \[PMC 4154083\]\(#\) !\[\]\(ddc5533caa0187e636e3d3234e0983a3\_img.jpg\) \[PMID 24926949\]\(#\).](#)
80. [Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, Quinn N, Lawton RC, Varvaris M, Van Straaten S, Gordon CM \(June 2012\). "Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens". The Journal of Clinical Endocrinology and Metabolism. 97 \(6\): 2134–42. \[doi:10.1210/jc.2011-3182\]\(#\). \[PMC 3387426\]\(#\) !\[\]\(7c207f8f59385c6dd11f9d9bdc7a0d1d\_img.jpg\) \[PMID 22456619\]\(#\).](#)
81. [Simek RZ, Prince J, Syed S, Sauer CG, Martineau B, Hofmekler T, et al. \(February 2016\). "Pilot Study Evaluating Efficacy of 2 Regimens for Hypovitaminosis D Repletion in Pediatric Inflammatory Bowel Disease". Journal of Pediatric Gastroenterology and Nutrition. 62 \(2\): 252–8. \[doi:10.1097/MPG.0000000000000915\]\(#\). \[PMC 4863642\]\(#\) !\[\]\(57a1bf910af99362b80b3ac4f2eecbac\_img.jpg\) \[PMID 26196201\]\(#\).](#)
82. [Hewison M \(2011\). "Vitamin D and innate and adaptive immunity". Vitamins and Hormones. Vitamins & Hormones. 86: 23–62. \[doi:10.1016/B978-0-12-386960-9.00002-2\]\(#\). \[ISBN 9780123869609\]\(#\). \[PMID 21419266\]\(#\).](#)
83. [Beard JA, Bearden A, Striker R \(March 2011\). "Vitamin D and the anti-viral state". Journal of Clinical Virology. 50 \(3\): 194–200. \[doi:10.1016/j.jcv.2010.12.006\]\(#\). \[PMC 3308600\]\(#\) !\[\]\(6b114000ab07dda576e2920e2dc838fa\_img.jpg\) \[PMID 21242105\]\(#\).](#)
84. [Spector SA \(Feb 2011\). "Vitamin D and HIV: letting the sun shine in". Topics in Antiviral Medicine. 19 \(1\): 6–10. \[PMID 21852710\]\(#\).](#)
85. [Nnoaham KE, Clarke A \(February 2008\). "Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis". International Journal of Epidemiology. 37 \(1\): 113–9. \[doi:10.1093/ije/dym247\]\(#\). \[PMID 18245055\]\(#\).](#)
86. [Luong KV, Nguyen LT \(June 2011\). "Impact of vitamin D in the treatment of tuberculosis". The American Journal of the Medical Sciences. 341 \(6\): 493–8. \[doi:10.1097/MAJ.0b013e3182070f47\]\(#\). \[PMID 21289501\]\(#\).](#)
87. [Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD \(2013\). "Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". PLoS One. 8 \(6\): e65835. \[Bibcode:2013PLoSO...865835B\]\(#\). \[doi:10.1371/journal.pone.0065835\]\(#\). \[PMC 3686844\]\(#\) !\[\]\(9129a6a4a4b11facb5cf665660eef788\_img.jpg\) \[PMID 23840373\]\(#\).](#)
88. [Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. \(February 2017\). "Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data". BMJ. 356: i6583. \[doi:10.1136/bmj.i6583\]\(#\). \[PMC 5310969\]\(#\) !\[\]\(7cbd4924d31aa4c46df484d5c5bf4696\_img.jpg\) \[PMID 28202713\]\(#\).](#)

89. [^ Autier P, Mullie P, Macacu A, Dragomir M, Boniol M, Coppens K, Pizot C, Boniol M \(2017\). "Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials". \*The Lancet. Diabetes & Endocrinology\*. \*\*5\*\*\(12\): 986–1004. doi:10.1016/S2213-8587\(17\)30357-1. PMID 29102433.](#)
90. [^ Yakoob MY, Salam RA, Khan FR, Bhutta ZA \(November 2016\). "Vitamin D supplementation for preventing infections in children under five years of age". \*The Cochrane Database of Systematic Reviews\*. John Wiley & Sons, Ltd. \*\*11\*\*: CD008824. doi:10.1002/14651858.cd008824.pub2. PMID 27826955.](#)
91. [^ Hart PH \(June 2012\). "Vitamin D supplementation, moderate sun exposure, and control of immune diseases". \*Discovery Medicine\*. \*\*13\*\* \(73\): 397–404. PMID 22742645.](#)
92. [^ Paul G, Brehm JM, Alcorn JF, Holguín F, Aujla SJ, Celedón JC \(January 2012\). "Vitamin D and asthma". \*American Journal of Respiratory and Critical Care Medicine\*. \*\*185\*\* \(2\): 124–32. doi:10.1164/rccm.201108-1502CI. PMC 3297088 . PMID 22016447.](#)
93. [^ Pakpoor J, Ramagopalan S \(13 December 2014\). "Evidence for an Association Between Vitamin D and Multiple Sclerosis". \*Current Topics in Behavioral Neurosciences\*. \*\*26\*\*: 105–15. doi:10.1007/7854\\_2014\\_358. ISBN 978-3-319-25541-5. PMID 25502544.](#) A substantial evidence base now exists supporting an association between vitamin D and MS ... Most notably, future work will need to establish appropriate dosing, timing and method of vitamin D supplementation in optimising any potential clinical benefit.
94. [^ Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J \(2013\). "A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis". \*Neuroepidemiology\(Systematic Review\)\*. \*\*40\*\* \(3\): 147–53. doi:10.1159/000345122. PMC 3649517 . PMID 23257784.](#) the available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS
95. [^ Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, Hanley DA, Pittas AG, Tjosvold L, Johnson JA \(October 2014\). "Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis". \*The Journal of Clinical Endocrinology and Metabolism \(Review\)\*. \*\*99\*\* \(10\): 3551–60. doi:10.1210/jc.2014-2136. PMC 4483466 . PMID 25062463.](#)
96. [^ Nakashima A, Yokoyama K, Yokoo T, Urashima M \(March 2016\). "Role of vitamin D in diabetes mellitus and chronic kidney disease". \*World Journal of Diabetes \(Review\)\*. \*\*7\*\* \(5\): 89–100. doi:10.4239/wjd.v7.i5.89. PMC 4781904 . PMID 26981182.](#)
97. [^ Shaffer JA, Edmondson D, Wasson LT, Falzon L, Homma K, Ezeokoli N, Li P, Davidson KW \(April 2014\). "Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials". \*Psychosomatic Medicine\*. \*\*76\*\* \(3\): 190–6. doi:10.1097/psy.0000000000000044. PMC 4008710 . PMID 24632894.](#)
98. [^ Balion C, Griffith LE, Striffler L, Henderson M, Patterson C, Heckman G, Llewellyn DJ, Raina P \(September 2012\). "Vitamin D, cognition, and dementia: a systematic review and meta-analysis". \*Neurology\*. \*\*79\*\* \(13\): 1397–405. doi:10.1212/WNL.0b013e31826c197f. PMC 3448747 . PMID 23008220.](#)
99. [^ to:² Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM \(March 2013\). "Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies". \*BMJ\*. \*\*346\*\*: f1169. doi:10.1136/bmj.f1169. PMID 23533188.](#)
100. [^ to:²²² Palacios C, De-Regil LM, Lombardo LK, Peña-Rosas JP \(November 2016\). "Vitamin D supplementation during pregnancy: Updated meta-analysis on maternal outcomes". \*The Journal of Steroid Biochemistry and Molecular Biology\*. \*\*164\*\*: 148–155. doi:10.1016/j.jsbmb.2016.02.008. PMID 26877200.](#)
101. [^ Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E \(November 2017\). "Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials". \*BMJ\*. \*\*359\*\*: j5237. doi:10.1136/bmj.j5237. PMID 29187358.](#)
102. [^ to:²² Wagner CL, Taylor SN, Dawodu A, Johnson DD, Hollis BW \(March 2012\). "Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus". \*Nutrients\*. \*\*4\*\* \(3\): 208–30. doi:10.3390/nu4030208. PMC 3347028 . PMID 22666547.](#)
103. [^ Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ \(May 2018\). "Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis". \*JAMA Pediatrics\*. doi:10.1001/jamapediatrics.2018.0302. PMID 29813153.](#)
104. [^ Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J \(June 2014\). "Vitamin D supplementation and body weight status: a systematic review and meta-analysis of randomized controlled trials". \*Obesity Reviews\*. \*\*15\*\* \(6\): 528–37. doi:10.1111/obr.12162. PMID 24528624.](#)
105. [^ Mallard SR, Howe AS, Houghton LA \(October 2016\). "Vitamin D status and weight loss: a systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials". \*The American Journal of Clinical Nutrition\*. \*\*104\*\* \(4\): 1151–1159. doi:10.3945/ajcn.116.136879. PMID 27604772.](#)
106. [^ to:²²² European Food Safety Authority \(EFSA\) Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(2010\). "Scientific opinion on the substantiation of health claims related to vitamin D and normal function of the immune system and inflammatory response \(ID 154, 159\), maintenance of normal muscle function \(ID 155\) and maintenance of normal cardiovascular function \(ID 159\) pursuant to Article 13\(1\) of Regulation \(EC\) No 1924/2006". \*EFSA Journal\*. \*\*8\*\* \(2\): 1468–85. doi:10.2903/j.efsa.2010.1468.](#)
107. [^ European Food Safety Authority \(EFSA\) Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(2011\). "Scientific opinion on the substantiation of a health claim related to vitamin D and risk of falling pursuant to Article 14 of Regulation \(EC\) No 1924/2006". \*EFSA Journal\*. \*\*9\*\* \(9\): 2382–2400. doi:10.2903/j.efsa.2011.2382.](#)
108. [^ "Guidance for Industry: A Food Labeling Guide \(11. Appendix C: Health Claims\) Food Labeling". US Food and Drug Administration. January 2013.](#)

109. [^ "Health Canada Scientific Summary on the U. S. Health Claim Regarding Calcium and Osteoporosis". Bureau of Nutritional Sciences Food Directorate, Health Products and Food Branch Health Canada. May 1, 2000.](#)
110. [^ "Regulatory Systems of Health Claims in Japan" \(PDF\). Japan Consumer Affairs Agency, Food Labelling Division. June 1, 2011.](#)
111. [^ "Vitamin D". Nutrient Reference Values for Australia and New Zealand. Australian Ministry of Health. September 9, 2005. Archived from \[the original\]\(#\) on February 27, 2012.](#)
112. [^ <sup>to:225</sup> "Vitamin D and Calcium: Updated Dietary Reference Intakes". Nutrition and Healthy Eating. Health Canada. Retrieved April 28, 2018.](#)
113. [^ <sup>to:225</sup> "Nutrient reference values for Australia and New Zealand" \(PDF\). National Health and Medical Research Council. September 9, 2005. Retrieved April 28, 2018.](#)
114. [^ <sup>to:225</sup> EFSA Panel on Dietetic Products, Nutrition and Allergies \(NDA\) \(29 June 2016\). "Dietary reference values for vitamin D". \[doi:10.2903/j.efsa.2016.4547\]\(#\). Retrieved 28 April 2018.](#)
115. [^ <sup>to:225</sup> EFSA Panel on Dietetic Products, Nutrition and Allergies \(NDA\). "Scientific Opinion on the Tolerable Upper Intake Level of vitamin D". Retrieved 28 April 2018.](#)
116. [^ "Federal Register May 27, 2016 Food Labeling: Revision of the Nutrition and Supplement Facts Labels. FR page 33982" \(PDF\).](#)
117. [^ "Changes to the Nutrition Facts Panel - Compliance Date"](#)
118. [^ Salleh A \(June 12, 2012\). "Vitamin D food fortification on the table". Australian Broadcasting Corporation.](#)
119. [^ "Vitamins and minerals – Vitamin D". National Health Service. February 18, 2015. Retrieved July 21, 2016.](#)
120. [^ "PHE publishes new advice on vitamin D". Public Health England. 21 July 2016. Retrieved 21 July 2016.](#)
121. [^ \*Vitamin-D-Bedarf bei fehlender endogener Synthese\* Deutsche Gesellschaft für Ernährung, January 2012](#)
122. [^ Pérez-López FR, Brincat M, Erel CT, Tremolieres F, Gambacciani M, Lambrinoudaki I, Moen MH, Schenck-Gustafsson K, Vujovic S, Rozenberg S, Rees M \(January 2012\). "EMAS position statement: Vitamin D and postmenopausal health". \*Maturitas\*. \*\*71\*\* \(1\): 83–8. \[doi:10.1016/j.maturitas.2011.11.002\]\(#\). \[PMID 22100145\]\(#\).](#)
123. [^ \*DRI. Dietary reference intakes: for calcium, phosphorus, magnesium, vitamin D, and fluoride\*. Washington, D.C.: National Academy Press. 1997. p. 250. \[ISBN 0-309-06350-7\]\(#\).](#)
124. [^ <sup>to:225</sup> Holick MF \(1992\). "Evolutionary biology and pathology of vitamin D". \*J. Nutr. Sci. Vitaminol. Spec No\*: 79–83. \[PMID 1297827\]\(#\).](#)
125. [^ <sup>to:225</sup> Keegan RJ, Lu Z, Bogusz JM, Williams JE, Holick MF \(January 2013\). "Photobiology of vitamin D in mushrooms and its bioavailability in humans". \*Dermato-Endocrinology\*. \*\*5\*\* \(1\): 165–76. \[doi:10.4161/derm.23321\]\(#\). \[PMC 3897585\]\(#\) !\[\]\(2dc8cdc0c918df88cde61039ecf68682\_img.jpg\). \[PMID 24494050\]\(#\).](#)
126. [^ <sup>to:225</sup> Wang T, Bengtsson G, Kärnefelt I, Björn LO \(September 2001\). "Provitamins and vitamins D<sub>2</sub> and D<sub>3</sub> in \*Cladina\* spp. over a latitudinal gradient: possible correlation with UV levels". \*Journal of Photochemistry and Photobiology. B, Biology\*. \*\*62\*\* \(1–2\): 118–22. \[doi:10.1016/S1011-1344\\(01\\)00160-9\]\(#\). \[PMID 11693362\]\(#\).](#)
127. [^ Haytowitz DB \(2009\). "Vitamin D in mushrooms" \(PDF\). Nutrient Data Laboratory, US Department of Agriculture. Retrieved 16 April 2018.](#)
128. [^ "Search, National Nutrient Database for Standard Reference Release 27". US Department of Agriculture, Agricultural Research Service. 2014. Retrieved 12 June 2015.](#)
129. [^ de Lourdes Samaniego-Vaesken M, Alonso-Aperte E, Varela-Moreiras G \(2012\). "Vitamin food fortification today". \*Food & Nutrition Research\*. \*\*56\*\*: 5459. \[doi:10.3402/fnr.v56i0.5459\]\(#\). \[PMC 3319130\]\(#\) !\[\]\(793119bf0d613bd9b598fb8668922511\_img.jpg\). \[PMID 22481896\]\(#\).](#)
130. [^ <sup>to:225</sup> Spiro A, Buttriss JL \(December 2014\). "Vitamin D: An overview of vitamin D status and intake in Europe". \*Nutrition Bulletin\*. \*\*39\*\* \(4\): 322–350. \[doi:10.1111/nbu.12108\]\(#\). \[PMC 4288313\]\(#\) !\[\]\(0a4819029e810ca9d2aba79260b63a4d\_img.jpg\). \[PMID 25635171\]\(#\).](#)
131. [^ U.S. Department of Health and Human Services \(July 15, 2016\). "Food Additives & Ingredients - Vitamin D for Milk and Milk Alternatives". U.S. Food and Drug Administration. Retrieved February 22, 2017.](#)
132. [^ "Federal Register: Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D2". Food and Drug Administration, US Department of Health and Human Services. July 18, 2016. Retrieved February 22, 2017.](#)
133. [^ Tripkovic L \(2013\). "Vitamin D<sub>2</sub> vs. vitamin D<sub>3</sub>: Are they one and the same?". \*Nutrition Bulletin - Wiley Online Library\*. \*\*38\*\*\(2\): 243–248. \[doi:10.1111/nbu.12029\]\(#\). Retrieved 2015-04-27.](#)
134. [^ Alshahrani F, Aljohani N \(September 2013\). "Vitamin D: deficiency, sufficiency and toxicity". \*Nutrients\*. \*\*5\*\* \(9\): 3605–16. \[doi:10.3390/nu5093605\]\(#\). \[PMC 3798924\]\(#\) !\[\]\(5b78a2fafd05db5e14d20573d68ef9b3\_img.jpg\). \[PMID 24067388\]\(#\). Retrieved 2015-04-27.](#)
135. [^ Biancuzzo RM, Clarke N, Reitz RE, Trivison TG, Holick MF \(March 2013\). "Serum concentrations of 1,25-dihydroxyvitamin D<sub>2</sub> and 1,25-dihydroxyvitamin D<sub>3</sub> in response to vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation". \*The Journal of Clinical Endocrinology and Metabolism\*. \*\*98\*\* \(3\): 973–9. \[doi:10.1210/jc.2012-2114\]\(#\). \[PMC 3590486\]\(#\) !\[\]\(25fe2c0d7244c22c84de6bda963b471d\_img.jpg\). \[PMID 23386645\]\(#\).](#)
136. [^ Borel P, Caillaud D, Cano NJ \(2015\). "Vitamin D bioavailability: state of the art". \*Critical Reviews in Food Science and Nutrition\*. \*\*55\*\* \(9\): 1193–205. \[doi:10.1080/10408398.2012.688897\]\(#\). \[PMID 24915331\]\(#\).](#)
137. [^ Jakobsen J, Knuthsen P \(April 2014\). "Stability of vitamin D in foodstuffs during cooking". \*Food Chemistry\*. \*\*148\*\*: 170–5. \[doi:10.1016/j.foodchem.2013.10.043\]\(#\). \[PMID 24262542\]\(#\).](#)
138. [^ Bischoff-Ferrari HA \(2014\). "Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes". \*Advances in Experimental Medicine and Biology \(Review\)\*. \*\*810\*\*: 500–25. \[doi:10.1007/978-0-387-77574-6\\\_5\]\(#\). \[PMID 25207384\]\(#\).](#)
139. [^ <sup>to:225</sup> Dahlquist DT, Dieter BP, Koehle MS \(2015\). "Plausible ergogenic effects of vitamin D on athletic performance and recovery". \*Journal of the International Society of Sports Nutrition \(Review\)\*. \*\*12\*\*: 33. \[doi:10.1186/s12970-015-0093-8\]\(#\). \[PMC 4539891\]\(#\) !\[\]\(d4bd0dc972749ad3ba477eac47688a0b\_img.jpg\). \[PMID 26288575\]\(#\).](#)

140. [Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, Bowden DW, Norris JM \(September 2008\). "Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans". \*The Journal of Clinical Endocrinology and Metabolism\*. \*\*93\*\* \(9\): 3381–8. doi:10.1210/jc.2007-2702. PMC 2567851. PMID 18593774.](#)
141. [Wang L, Song Y, März S, Pilz S, März W, Michaëlsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD \(2012\). "Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies". \*Circulation: Cardiovascular Quality and Outcomes\*. \*\*5\*\* \(6\): 819–29. doi:10.1161/CIRCOUTCOMES.112.967604. PMC 3510675. PMID 23149428.](#)
142. [Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA \(January 2011\). "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know". \*The Journal of Clinical Endocrinology and Metabolism\*. \*\*96\*\* \(1\): 53–8. doi:10.1210/jc.2010-2704. PMC 3046611. PMID 21118827.](#)
143. [Vitamin D at Merck Manual of Diagnosis and Therapy Professional Edition](#)
144. [Vieth R \(May 1999\). "Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety" \(PDF\). \*The American Journal of Clinical Nutrition\*. \*\*69\*\* \(5\): 842–56. PMID 10232622.](#)
145. [Tolerable Upper Intake Limits for Vitamins And Minerals \(PDF\). \*European Food Safety Authority\*. December 2006. ISBN 92-9199-014-0.](#)
146. [DeLancey S \(June 15, 2010\). "FDA Cautions on Accurate Vitamin D Supplementation for Infants". Press Announcement. U.S. Food and Drug Administration.](#)
147. [Olmos-Ortiz A, Avila E, Durand-Carbajal M, Díaz L \(January 2015\). "Regulation of calcitriol biosynthesis and activity: focus on gestational vitamin D deficiency and adverse pregnancy outcomes". \*Nutrients\*. \*\*7\*\* \(1\): 443–80. doi:10.3390/nu7010443. PMC 4303849. PMID 25584965.](#)
148. [Holick MF \(April 1987\). "Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables". \*Federation Proceedings\*. \*\*46\*\* \(5\): 1876–82. PMID 3030826.](#)
149. [Deluca HF \(January 2014\). "History of the discovery of vitamin D and its active metabolites". \*BoneKey Reports\*. \*\*3\*\*: 479. doi:10.1038/bonekey.2013.213. PMC 3899558. PMID 24466410.](#)
150. [Holick MF \(March 2004\). "Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis". \*The American Journal of Clinical Nutrition\*. \*\*79\*\* \(3\): 362–71. PMID 14985208.](#)
151. [Eyley SC, Williams DH \(1975\). "Photolytic production of vitamin D. The preparative value of a photo-sensitiser". \*Journal of the Chemical Society, Chemical Communications\* \(20\): 858a. doi:10.1039/C3975000858A.](#)
152. [Keegan RJ, Lu Z, Bogusz JM, Williams JE, Holick MF \(January 2013\). "Photobiology of vitamin D in mushrooms and its bioavailability in humans". \*Dermato-Endocrinology\*. \*\*5\*\* \(1\): 165–76. doi:10.4161/derm.23321. PMC 3897585. PMID 24494050.](#)
153. [Crissey SD, Ange KD, Jacobsen KL, Slifka KA, Bowen PE, Stacewicz-Sapuntzakis M, Langman CB, Sadler W, Kahn S, Ward A \(January 2003\). "Serum concentrations of lipids, vitamin d metabolites, retinol, retinyl esters, tocopherols and selected carotenoids in twelve captive wild felid species at four zoos". \*The Journal of Nutrition\*. \*\*133\*\* \(1\): 160–6. PMID 12514284.](#)
154. [Hume EM, Lucas NS, Smith HH \(1927\). "On the Absorption of Vitamin D from the Skin". \*The Biochemical Journal\*. \*\*21\*\* \(2\): 362–7. doi:10.1042/bj0210362. PMC 1251921. PMID 16743844.](#)
155. [C. Claiborne Ray \(May 17, 2005\). "Sunshine Vitamin D". \*The New York Times\*. Archived from the original on February 21, 2013. Retrieved March 8, 2013.](#)
156. [Bolton J. "UV FAQs". \*International Ultraviolet Association\*. Archived from the original on May 30, 2013.](#)
157. [Holick MF \(February 2002\). "Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health". \*Current Opinion in Endocrinology, Diabetes and Obesity\*. \*\*9\*\* \(1\): 87–98. doi:10.1097/00060793-200202000-00011.](#)
158. [Holick MF \(September 2002\). "Sunlight and vitamin D: both good for cardiovascular health". \*Journal of General Internal Medicine\*. \*\*17\*\* \(9\): 733–5. doi:10.1046/j.1525-1497.2002.20731.x. PMC 1495109. PMID 12220371.](#)
159. [Holick MF, Smith E, Pincus S \(December 1987\). "Skin as the site of vitamin D synthesis and target tissue for 1,25-dihydroxyvitamin D3. Use of calcitriol \(1,25-dihydroxyvitamin D3\) for treatment of psoriasis". \*Archives of Dermatology\*. \*\*123\*\* \(12\): 1677–1683a. doi:10.1001/archderm.1987.01660360108022. PMID 2825606.](#)
160. [Institute of Medicine \(US\) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium \(2011\). "8. Implications and Special Concerns". In Ross AC, Taylor CL, Yaktine AL, Del Valle HB. \*Dietary Reference Intakes for Calcium and Vitamin D\*. Washington DC: National Academies Press. ISBN 0-309-16394-3. PMID 21796828.](#)
161. ["Anatomy of the skin". \*National Cancer Institute, US National Institutes of Health, Bethesda\*. 2016. Retrieved 19 December 2016.](#)
162. ["Vitamin D and Skin Health". \*LINUS PAULING INSTITUTE Micronutrient Information Center\*. Oregon State University. Retrieved 30 March 2017.](#)
163. [Holick, Michael F. \(1 April 2010\). \*The Vitamin D Solution: A 3-Step Strategy to Cure Our Most Common Health Problems\*. Penguin Publishing Group. ISBN 978-1-101-22293-5.](#)
164. [Agarwal SC, Stout SD \(28 June 2011\). \*Bone Loss and Osteoporosis: An Anthropological Perspective\*. Springer Science & Business Media. ISBN 978-1-4419-8891-1. Archived \(PDF\) from the original on 29 January 2006. The high 25\(OH\)D concentrations, and relatively high vitamin D requirements of apes and monkeys are understandable in light of their biology—their body surface area relative to mass is generally greater than for humans, and they are inveterate groomers, consuming by mouth the vitamin D generated from the oils secreted by skin into fur. Although much of the](#)

vitamin D produced within human skin is absorbed directly, birds and furbearing animals acquire most of their vitamin D orally, as they groom themselves (Bicknell and Prescott, 1946; Carpenter and Zhao, 1999). Vitamin D is generated from the oily secretions of skin into fur. The oral consumption of UV-exposed dermal excretion is the way many animals acquire the "nutrient," vitamin D. Although Fraser (1983) has argued that dermal absorption of vitamin D may be more natural, what we know from animals indicates that oral consumption is equally physiological. Since vitamin D can be extracted from UV-exposed human sweat and skin secretions (Bicknell and Prescott, 1946), it is also reasonable to think that early humans obtained some of their vitamin D by mouth as well, by licking the skin.

165. [^](#) Yahav S, Buffenstein R (January 1993). "Cholecalciferol supplementation alters gut function and improves digestibility in an underground inhabitant, the naked mole rat (*Heterocephalus glaber*), when fed on a carrot diet". *The British Journal of Nutrition*. **69** (1): 233–41. doi:10.1079/BJN19930025. PMID 8384476.
166. [^](#) [to:^^](#) Holick MF (November 2005). "The vitamin D epidemic and its health consequences" (PDF). *The Journal of Nutrition*. **135**(11): 2739S–48S. PMID 16251641. [Vitamin D3] is produced commercially by extracting 7-dehydrocholesterol from wool fat, followed by UVB irradiation and purification [...] [Vitamin D2] is commercially made by irradiating and then purifying the ergosterol extracted from yeast
167. [^](#) Takeuchi A, Okano T, Sayamoto M, Sawamura S, Kobayashi T, Motosugi M, Yamakawa T (February 1986). "Tissue distribution of 7-dehydrocholesterol, vitamin D3 and 25-hydroxyvitamin D3 in several species of fishes". *Journal of Nutritional Science and Vitaminology*. **32** (1): 13–22. doi:10.3177/insv.32.13. PMID 3012050.
168. [^](#) [to:^^s^](#) Adams JS, Hewison M (February 2010). "Update in vitamin D". *The Journal of Clinical Endocrinology and Metabolism*. **95** (2): 471–8. doi:10.1210/jc.2009-1773. PMC 2840860 . PMID 20133466.
169. [^](#) [to:^^s^](#) Bikle, DD (20 March 2014). "Vitamin D metabolism, mechanism of action, and clinical applications". *Chemistry & biology*. **21** (3): 319–29. doi:10.1016/j.chembiol.2013.12.016. PMC 3968073 . PMID 24529992.
170. [^](#) Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (May 2004). "Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase". *Proceedings of the National Academy of Sciences of the United States of America*. **101** (20): 7711–5. Bibcode:2004PNAS...101.7711C. doi:10.1073/pnas.0402490101. PMC 419671 . PMID 15128933.
171. [^](#) Laing CJ, Cooke NE (2004). "Section I: Ch. 8: Vitamin D Binding Protein". In Feldman D, Glorieux FH, Pike JW. *Vitamin D*. 1 (2 ed.). Academic Press. pp. 117–134. ISBN 0122526872.
172. [^](#) "IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN): Nomenclature of vitamin D. Recommendations 1981". *European Journal of Biochemistry*. **124** (2): 223–7. 17 May 1982. doi:10.1111/j.1432-1033.1982.tb06581.x. PMID 7094913.
173. [^](#) Holick MF, Kleiner-Bossaller A, Schnoes HK, Kasten PM, Boyle IT, DeLuca HF (October 1973). "1,24,25-Trihydroxyvitamin D3. A metabolite of vitamin D3 effective on intestine". *The Journal of Biological Chemistry*. **248** (19): 6691–6. PMID 4355503.
174. [^](#) Horst RL, Reinhardt TA, Ramberg CF, Koszewski NJ, Napoli JL (July 1986). "24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process". *The Journal of Biological Chemistry*. **261** (20): 9250–6. PMID 3013880.
175. [^](#) "Age-old children's disease back in force". *Thestar.com*. July 25, 2007. Archived from [the original](#) on May 17, 2008. Retrieved August 24, 2010.
176. [^](#) Elena Conis (July 24, 2006). "Fortified foods took out rickets". *Los Angeles Times*. Retrieved August 24, 2010.
177. [^](#) McClean FC, Budy AM (January 28, 1964). "Vitamin A, Vitamin D, Cartilage, Bones, and Teeth". *Vitamins and Hormones*. **21**. Academic Press. pp. 51–52. ISBN 978-0-12-709821-0.
178. [^](#) "History of Vitamin D". University of California at Riverside. 2011. Retrieved May 9, 2014.
179. [^](#) "Adolf Windaus – Biography". *Nobelprize.org*. March 25, 2010. Retrieved March 25, 2010.
180. [^](#) Rosenheim O, King H (1932). "The Ring-system of sterols and bile acids. Part II". *J. Chem. Technol. Biotechnol*. **51** (47): 954–7. doi:10.1002/jctb.5000514702.
181. [^](#) Askew FA, Bourdillon RB, Bruce HM, Callow RK, St. L. Philpot J, Webster TA (1932). "Crystalline Vitamin D". *Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character*. **109** (764): 488–506. doi:10.1098/rspb.1932.0008. JSTOR 81571.
182. [^](#) Hirsch AL (2011). "Industrial aspects of vitamin D". In Feldman DJ, Pike JW, Adams JS. *Vitamin D*. London; Waltham, MA: Academic Press. p. 73. ISBN 978-0-12-387035-3.
183. [^](#) Ziedonis AA, Mowery DC, Nelson RR, Bhaven NS (2004). *Ivory tower and industrial innovation: university-industry technology transfer before and after the Bayh-Dole Act in the United States*. Stanford, Calif: Stanford Business Books. pp. 39–40. ISBN 0-8047-4920-5.
184. [^](#) Marshall, James (September 2010). *Elbridge a Stuart: Founder of Carnation Company*. Kessinger Publishing. ISBN 978-1-164-49678-6.
185. [^](#) Haussler MR, Norman AW (January 1969). "Chromosomal receptor for a vitamin D metabolite". *Proceedings of the National Academy of Sciences of the United States of America*. **62** (1): 155–62. Bibcode:1969PNAS...62..155H. doi:10.1073/pnas.62.1.155. PMC 285968 . PMID 5253652.
186. [^](#) Holick MF, Schnoes HK, DeLuca HF (April 1971). "Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine". *Proceedings of the National Academy of Sciences of the United States of America*. **68** (4): 803–4. Bibcode:1971PNAS...68..803H. doi:10.1073/pnas.68.4.803. PMC 389047 . PMID 4323790.
187. [^](#) Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V, Popják G (July 1971). "1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine". *Science*. **173** (3991): 51–4. Bibcode:1971Sci...173...51N. doi:10.1126/science.173.3991.51. PMID 4325863.



188. [^ Holick MF, DeLuca HF, Avioli LV \(January 1972\). "Isolation and identification of 25-hydroxycholecalciferol from human plasma". \*Archives of Internal Medicine\*. \*\*129\*\* \(1\): 56–61. doi:10.1001/archinte.1972.00320010060005. PMID 4332591.](#)
189. [^ Dankers W, Colin EM, van Hamburg JP, Lubberts E \(2016\). "\*Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential\*". \*Front Immunol\*. \*\*7\*\*: 697. doi:10.3389/fimmu.2016.00697. PMC 5247472. PMID 28163705.](#)
190. [^ <sup>a</sup> Heaney RP, Holick MF \(March 2011\). "Why the IOM recommendations for vitamin D are deficient". \*Journal of Bone and Mineral Research\*. \*\*26\*\* \(3\): 455–7. doi:10.1002/jbmr.328. PMID 21337617.](#)
191. [^ Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM \(July 2011\). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline". \*The Journal of Clinical Endocrinology and Metabolism\*. \*\*96\*\* \(7\): 1911–30. doi:10.1210/jc.2011-0385. PMID 21646368.](#)
192. [^ "\*ODS Vitamin D Initiative\*". Bethesda, MD: Office of Dietary Supplements, US National Institutes of Health. 2014.](#)
193. [^ Pyrzak B, Witkowska-Sędek E, Krajewska M, Demkow U, Kucharska AM \(2015\). "Metabolic and immunological consequences of vitamin D deficiency in obese children". \*Advances in Experimental Medicine and Biology\*. \*Advances in Experimental Medicine and Biology\*. \*\*840\*\*: 13–9. doi:10.1007/5584\\_2014\\_81. ISBN 978-3-319-10249-8. PMID 25315624.](#)
194. [^ "\*How is vitamin D being studied now in clinical cancer research?\*". Bethesda, MD: National Cancer Institute, US National Institutes of Health. 21 October 2013.](#)
195. [^ Cashman KD, Dowling KG, Škrabáková Z, Gonzalez-Gross M, Valtueña J, De Henauw S, et al. \(April 2016\). "\*Vitamin D deficiency in Europe: pandemic?\*". \*The American Journal of Clinical Nutrition\*. \*\*103\*\* \(4\): 1033–44. doi:10.3945/ajcn.115.120873. PMID 26864360.](#)
196. [^ Sarkar FH, Li Y, Wang Z, Kong D \(September 2010\). "\*The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer\*". \*Cancer Metastasis Reviews\*. \*\*29\*\* \(3\): 383–94. doi:10.1007/s10555-010-9233-4. PMC 2974632. PMID 20711635.](#)

